Exhibit 10.5

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

LICENSE AGREEMENT

This LICENSE AGREEMENT (the “Agreement”), effective as of March 31, 2011 (the
“Effective Date”), is made by and between Sunesis Pharmaceuticals, Inc., a
Delaware corporation, having a principal place of business at 395 Oyster Point
Boulevard, Suite 400, South San Francisco, CA 94080 (“Sunesis”), and Millennium
Pharmaceuticals, Inc., a Delaware corporation, having a principal place of
business at 40 Landsdowne Street, Cambridge, Massachusetts 02139 (“Millennium”).
Sunesis and Millennium are sometimes referred to herein individually as a
“Party” and collectively as the “Parties”.

BACKGROUND

A. Sunesis has developed proprietary technology and know-how for the discovery
and optimization of small molecules that bind to enzyme targets and
protein-protein interfaces, with special expertise towards kinases.

B. Pursuant to a Collaboration Agreement effective as of August 27, 2004 (the
“Original Agreement Effective Date”) by and between Sunesis and Biogen Idec MA
Inc. (“Biogen Idec”), as amended prior to the Effective Date (the “Original
Agreement”), Sunesis and Biogen Idec collaborated on the discovery and
development of small molecules that modulated Collaboration Targets (as defined
in the Original Agreement), and discovered and commenced development of several
compounds, including compounds designated as BIIB024 and [ * ] (each a “Licensed
Compound”, as further defined below), it being understood that BIIB024 has been
designated as a “Development Candidate” under the terms of the Original
Agreement.

C. Pursuant to a Termination and Transition Agreement dated as of the Effective
Date (the “Three Party Agreement”), Sunesis, Biogen Idec and Millennium have
agreed that (i) Millennium shall succeed to the rights of Biogen Idec under the
Original Agreement with respect to the Licensed Compounds and, in order to
effectuate the foregoing, (ii) Sunesis and Millennium shall enter into this
Agreement, Sunesis and Biogen Idec shall enter into an amendment and restatement
of the Original Agreement (the “New Sunesis-Biogen Agreement”), and Millennium
and Biogen Idec shall enter into an asset transfer agreement (the
“Millennium-Biogen Agreement”).

NOW, THEREFORE, for and in consideration of the covenants, conditions and
undertakings hereinafter set forth, it is agreed by and between the Parties as
follows:

ARTICLE 1

DEFINITIONS

As used herein, the following terms will have the meanings set forth below:

1.1. “Affiliate” of a Person shall mean any corporation or other business entity
that during the Term of this Agreement controls, is controlled by or is under
common control with such Person but only for so long as such entity controls, is
controlled by, or is under common control with such Person. With respect to a
particular entity, “control” shall mean the ownership

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

directly or indirectly of fifty percent (50%) or more of the stock entitled to
vote for the election of directors, and for nonstock organizations, of the
equity interests entitled to control the management of such entity. [ * ].

1.2. “Biogen Idec Collaboration Technology” shall mean all Biogen Idec
Collaboration Patents and Biogen Idec Collaboration Know-How.

1.2.1 “Biogen Idec Collaboration Patents” shall mean (a) those Patent Rights set
forth on Exhibit 1.4, the subject of which is an invention: (i) conceived in the
course of performing the Research Program during the Research Term and reduced
to practice prior to the Effective Date solely by or under authority of
personnel of Biogen Idec or any of its controlled Affiliates; or (ii) conceived
and reduced to practice solely by or under authority of personnel of Biogen Idec
or any of its controlled Affiliates after the Original Agreement Effective Date
but prior to the Effective Date, in the case of either (i) or (ii) in the course
of activities [ * ] to the Designated Targets or to the discovery, research, or
development of Licensed Compounds or Licensed Products; and (b) all Patent
Rights that arise during the Term that claim or cover any Biogen Idec
Collaboration Know-How. Notwithstanding the foregoing, Biogen Idec Collaboration
Patents shall in all cases exclude Sunesis Core Technology, Joint Sunesis-Biogen
Collaboration Patents and Sunesis Collaboration Patents.

1.2.2 “Biogen Idec Collaboration Know-How” shall mean any Know-How: (i) made or
developed solely by or under authority of personnel of Biogen Idec or any of its
controlled Affiliates in the course of performing the Research Program during
the Research Term; or (ii) made or developed solely by or under authority of
personnel of Biogen Idec or any of its controlled Affiliates after the Original
Agreement Effective Date but prior to the Effective Date, in the case of either
(i) or (ii) in the course of activities [ * ] to the Designated Targets or to
the discovery, research, or development of Licensed Compounds or Licensed
Products. Notwithstanding the foregoing, Biogen Idec Collaboration Know-How
shall in all cases exclude Sunesis Core Technology, Joint Sunesis-Biogen
Collaboration Know-How and Excluded Compounds (as defined in the Original
Agreement).

1.3. “Co-Funding Option” shall mean the option of Sunesis to fund a portion of
the post-Phase I Development Costs of a Licensed Product in the Co-Funded
Territory as provided in Section 2.2. The “Co-Funded Territory” shall have the
meaning set forth in Section 2.2.1.

1.4. “Collaboration Technology” shall mean all Collaboration Patents and
Collaboration Know-How.

1.4.1 “Collaboration Patents” shall mean all Biogen Idec Collaboration Patents,
Sunesis Collaboration Patents and Joint Sunesis-Biogen Collaboration Patents.
Exhibit 1.4 sets forth the Collaboration Patents existing as of the Effective
Date.

1.4.2 “Collaboration Know-How” shall mean all Biogen Idec Collaboration
Know-How, Sunesis Collaboration Know-How and Joint Sunesis-Biogen Collaboration
Know-How.

 

-2-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

1.5. “Combination Product” shall mean any of (i) a Licensed Product that
incorporates two or more active drug substances including a Licensed Compound,
or (ii) a Reverted Licensed Product that incorporates two or more active drug
substances including a Reverted Compound; in each case where at least one of the
active drug substances is neither a Licensed Compound nor a Reverted Compound
(respectively).

1.6. “Commercially Reasonable and Diligent Efforts” shall mean the level of
effort and resources normally used by a Party for a product or compound owned or
controlled by it, which is of similar market potential and at a similar stage in
its development or product life, taking into account, without limitation, with
respect to a product issues of safety and efficacy, product profile, the
proprietary position of the product, the then current competitive environment
for the product and the likely timing of the product’s entry into the market,
the regulatory environment of the product, and other relevant scientific,
technical and commercial factors. Notwithstanding the foregoing, to the extent
that the performance of a Party’s responsibilities hereunder is adversely
affected by the other Party’s failure to perform its responsibilities hereunder,
such Party shall not be deemed to have failed to use its Commercially Reasonable
and Diligent Efforts in performing such responsibilities. Notwithstanding, but
not in limitation of the foregoing, Millennium shall be deemed to be using
Commercially Reasonable and Diligent Efforts for a Co-Funded Product
specifically directed at a particular Designated Target if it is using
Commercially Reasonable and Diligent Efforts with respect to a Licensed Compound
specifically directed at such Designated Target.

1.7. “Confidential Information” shall mean, with respect to a Party, all
information (and all tangible and intangible embodiments thereof), which is
owned or controlled by such Party, and is disclosed by such Party to the other
Party pursuant to this Agreement. Notwithstanding the foregoing, Confidential
Information of a Party shall not include information which, and only to the
extent, the receiving Party can establish by written documentation (a) has been
generally known prior to disclosure of such information by the disclosing Party
to the receiving Party; (b) has become generally known, without the fault of the
receiving Party, subsequent to disclosure of such information by the disclosing
Party to the receiving Party; (c) has been received by the receiving Party at
any time from a source, other than the disclosing Party, rightfully having
possession of and the right to disclose such information free of confidentiality
obligations; (d) has been otherwise known by the receiving Party free of
confidentiality obligations prior to disclosure of such information by the
disclosing Party to the receiving Party; or (e) is independently developed
without reference to or use of the Confidential Information of the disclosing
Party. For clarity, except as otherwise expressly provided in this Agreement,
Sunesis Collaboration Technology and Joint Sunesis-Biogen Collaboration
Technology shall be deemed Confidential Information of both Millennium and
Sunesis. For clarity, Biogen Idec Collaboration Technology and Development
Technology shall be deemed Confidential Information solely of Millennium.

1.8. “Control” or “Controlled” shall mean, with respect to any Patent Rights or
Know-how and with respect to any Person, possession (whether by ownership or
license, other than a license granted pursuant to this Agreement) by such Person
or its Affiliate of the ability to grant

 

-3-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

the licenses or sublicenses as provided for herein without violating the terms
of any agreement or other arrangement with any Third Party.

1.9. “Covered” shall mean, with respect to a compound and a Valid Claim, that
the manufacture, use, sale, offer for sale or importation of such compound, but
for the licenses or ownership rights granted herein, would infringe such Valid
Claim.

1.10. “Designated Targets” shall mean (i) the Raf Target and (ii) the [ * ]
Target.

1.11. “Development” shall mean all research, development and regulatory
activities regarding the Licensed Products. “Development” shall include all
activities related to research, optimization and design of the appropriate
molecule and identification of back-ups, preclinical testing, test method
development and stability testing, toxicology, formulation, process development,
manufacturing scale-up, qualification and validation, quality assurance/quality
control, clinical studies, manufacturing clinical supplies, regulatory affairs,
statistical analysis and report writing, technology transfer, market research
and development, and all other pre-approval and related post-approval
activities. When used as a verb, “Develop” shall mean to engage in Development.

1.12. “Development Candidate” shall mean any Licensed Compound that enters into
GLP clinical toxicology testing or GMP manufacturing.

1.13. “Development Costs” shall mean the costs and expenses associated with
Development activities actually incurred by Millennium or its Affiliates for a
particular Licensed Product during the measurement period and in the territories
described in Section 2.2.4(c). The costs and expenses associated with
Development activities shall include [ * ] In determining “Development Costs”
chargeable under this Agreement, Millennium will use its project accounting
systems, and will review its project accounting systems and methodologies with
Sunesis. The Parties hereby agree that efforts of the employees of Millennium or
its Affiliates in performing its activities hereunder shall be charged as
Development Costs at the FTE Rate. Notwithstanding anything in this Section 1.13
to the contrary, only those Development Costs that are contemplated by the
Co-Development Plan and Budget or were otherwise approved by the JSC shall be
chargeable by Millennium as Development Costs. It is further understood that the
activities of the following groups or functions shall not be chargeable as
Development Costs: [ * ]. All payments made by Millennium to a Third Party in
connection with the performance of its activities under the Co-Development Plan
and Budget shall be charged as Development Costs at Millennium’s actual
out-of-pocket cost. Expenses incurred by Millennium for equipment, materials and
supplies utilized in performing its activities under the Co-Development Plan and
Budget shall not be separately charged as Development Costs, except for those
expenses incurred by Millennium, with the prior written consent of the JSC as
set forth in the Co-Development Plan and Budget, in the purchase or making of [
* ], and the like) that are to be used exclusively in connection with the
performance of Millennium’s activities under the Co-Development Plan and Budget
(e.g., [ * ] etc.), which expenses shall be charged as Developments Cost at
Millennium’s actual out-of-pocket expense incurred in purchasing or making such
[ * ].

 

-4-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

1.14. “Development Technology” shall mean any Know-How that is made or developed
after the Effective Date and during the Term solely by or under authority of
either Party or its Affiliates, or jointly by or under authority of both Parties
or their respective Affiliates, in the course of performing any activity under
this Agreement [ * ] to a Designated Target or [ * ] to the Development,
manufacturing or commercialization of a Licensed Compound or Licensed Product,
and all Patent Rights that arise during the Term that claim or cover any such
Know-How. Notwithstanding the foregoing, Development Technology shall in all
cases exclude Biogen Idec Collaboration Patents, Biogen Idec Collaboration
Know-How, Sunesis Collaboration Technology, Sunesis Core Technology, Joint
Sunesis-Biogen Collaboration Patents and Joint Sunesis-Biogen Collaboration
Know-How.

1.15. “Diligence Summary” shall mean, with respect to a particular Product, a
summary of Development and commercialization activities with respect to such
Product, that (i) were performed by the reporting Party or its Third Party
collaborators in the previous [ * ] period (or shorter period from the prior
Diligence Summary, if applicable), and (ii) as of the date of the Diligence
Summary, are planned in good faith for the following [ * ] period. For clarity,
it is understood and acknowledged that in providing a Diligence Summary, a Party
shall not be required to disclose scientific results, specific research
activities or the identity of any Third Party collaborator or potential
collaborator, but shall at a minimum provide a summary of the total number of
FTEs dedicated or planned to be dedicated to the Development and
commercialization of such Product, and a summary of the functional allocation of
such FTEs.

1.16. “Field” shall mean the treatment, prevention or diagnosis of disease in
humans and animals.

1.17. “FTE” shall mean, with respect to a Party, the equivalent of the work time
of a full-time clinician, regulatory or other qualified person over a
twelve-month period (including normal vacations, sick days and holidays), equal
to at least [ * ] ([ * ]) weeks of work. In the case of less than a full-time
person, the portion of an FTE year devoted by such person to Development
activities shall be determined by dividing the number of days during any
twelve-month period devoted by such person to Development activities by the
total number of working days of such person during such twelve-month period.
“FTE Rate” for Millennium shall mean $[ * ] per annum per FTE from the Effective
Date through December 31, 2011. Thereafter, the FTE Rate will be adjusted by the
Inflation Index. As used herein, “Inflation Index” shall mean the percentage
increase in the Consumer Price Index for all Urban Consumers, as published by
the U.S. Department of Labor, Bureau of Statistics, since the Effective Date.
For clarity, the FTE rate for sales representatives involved in co-promotion
shall be determined in accordance with Section 3.2.3.

1.18. “Governmental Authority” shall mean any multi-national, federal, state,
local, municipal or other government authority of any nature (including any
governmental division, prefecture, subdivision, department, agency, bureau,
branch, office, commission, council, court or other tribunal).

 

-5-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

1.19. “Gross Sales” shall mean the gross amount invoiced by either Party or its
Affiliates or permitted Sublicensees for sales of a Product. However, Gross
Sales shall not include amounts received by such Party (or any of its
Affiliates) from transactions with an Affiliate or Sublicensee, where the
Product in question will be resold by such Affiliate or Sublicensee to an
independent Third Party distributor, agent or end user and such amounts received
by the Affiliate or Sublicensee from such resale is included in Gross Sales.

1.20. “Joint Sunesis-Biogen Collaboration Technology” shall mean all Joint
Sunesis-Biogen Collaboration Patents and Joint Sunesis-Biogen Collaboration
Know-How.

1.20.1 “Joint Sunesis-Biogen Collaboration Patents” shall mean (a) those Patent
Rights set forth on Exhibit 1.4, the subject of which is an invention:
(i) conceived in the course of performing the Research Program during the
Research Term and reduced to practice prior to the Effective Date jointly by, or
under authority of, both Sunesis and Biogen Idec; (ii) conceived and reduced to
practice jointly by, or under authority of, Sunesis and Biogen Idec after the
Original Agreement Effective Date but prior to the Effective Date, in the case
of either (i) or (ii) in the course of activities [ * ] to the Designated
Targets or to the discovery, research, or development of Licensed Compounds or
Licensed Products; or (iii) conceived in the course of performing the Research
Program during the Research Term and reduced to practice prior to the Effective
Date using Joint Sunesis-Biogen Collaboration Know-How, Sunesis Collaboration
Know-How or Sunesis Core Technology by or under authority of personnel of Biogen
Idec or any of its controlled Affiliates; and (b) all Patent Rights that arise
during the Term that claim or cover any Joint Sunesis-Biogen Collaboration
Know-How. For clarity, the inventions described in subsection (a)(iii) above are
limited to those inventions [ * ] or comprising compositions of matter that
modulate Designated Targets or methods of use thereof in modulating Designated
Targets. Notwithstanding the foregoing, Joint Sunesis-Biogen Collaboration
Patents shall in all cases exclude Sunesis Core Technology, Biogen Idec
Collaboration Patents and Sunesis Collaboration Patents.

1.20.2 “Joint Sunesis-Biogen Collaboration Know-How” shall mean any Know-How:
(i) made or developed jointly by, or under authority of, both Sunesis and Biogen
Idec in the course of performing the Research Program during the Research Term;
(ii) made or developed jointly by, or under authority of, both Sunesis and
Biogen Idec after the Original Agreement Effective Date but prior to the
Effective Date, in the case of either (i) or (ii) in the course of activities [
* ] to the Designated Targets or to the discovery, research, or development of
Licensed Compounds or Licensed Products.

1.21. “Know-How” shall mean any data, inventions, invention disclosures,
methods, proprietary information, processes, techniques, technology, or material
(including biological or other materials).

1.22. “Licensed Compounds” shall mean (i) BIIB024, (ii) [ * ], (iii) the other
compounds set forth on Exhibit F or Exhibit G of the Millennium-Biogen
Agreement, (iv) all other compounds that were Synthesized in the course of
performing the Research Program during the Research Term in connection with
activities relating to a Designated Target, (v) all

 

-6-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

other compounds claimed or covered by a Collaboration Patent, (vi) all other
compounds claimed or covered by an invention disclosure within the Collaboration
Know-How, (vii) all compounds Synthesized [ * ] period following the Effective
Date by or on behalf of Millennium in the course of activities directed to the [
* ] Target and through use of the Sunesis Licensed Technology, and (viii) all
salts, prodrugs, esters, metabolites, solvates, stereoisomers and polymorphs of
any of the foregoing.

1.23. “Licensed Product” shall mean a pharmaceutical preparation for sale by
prescription, over-the-counter, or any other method for all uses in humans or
animals, which incorporates one or more Licensed Compounds as an active drug
substance, but excluding Reverted Licensed Products. It is understood that
Licensed Products containing different active ingredient(s) (i.e., a different
active ingredient or an additional active ingredient) or a different formulation
shall be deemed different “Licensed Products”.

1.24. “NDA” shall mean a New Drug Application (or its equivalent), as defined in
the U.S. Food, Drug and Cosmetic Act and the regulations promulgated thereunder,
or any corresponding or similar application, registration or certification in
any jurisdiction for marketing authorization of a Product.

1.25. “Net Sales” shall mean, with respect to a Product, Gross Sales less
applicable Sales Returns and Allowances.

If a sale, transfer or other disposition with respect to a Product is made for
consideration other than cash or is not at arm’s length, then the Net Sales from
such sale, transfer or other disposition shall be the arm’s length fair market
value thereof. For purposes of this Agreement, “sale” shall mean any transfer or
other distribution or disposition, but shall not include transfers or other
distributions or dispositions of Product, at no charge, for pre-clinical,
clinical or regulatory purposes or in connection with patient assistance
programs or other charitable purposes or to physicians or hospitals for
promotional purposes.

In the event that a Product is sold in the form of a Combination Product, Net
Sales for the Product shall be determined by multiplying actual Net Sales of the
Combination Product (determined by reference to the definition of Net Sales set
forth above) during the royalty payment period by the fraction A/(A+B) where A
is the average sale price of the Product as the sole active drug substance when
sold separately in finished form, and B is the average sales price of products
containing only the other active ingredients when sold separately in finished
form, in each case during the applicable royalty payment period in the country
in which the sale of the Combination Product was made, or if sales of both types
of products did not occur in such period, then in the most recent royalty
payment period in which sales of both occurred. Where the Product is sold
separately in finished form but the other ingredients are not, Net Sales for the
Product shall be determined by multiplying actual Net Sales of the Combination
Product (determined by reference to the definition of Net Sales set forth above)
during the royalty payment period by the ratio of the average per-unit sale
price of the Product when sold separately in finished form to the average
per-unit Net Sales of the Combination Product, in each case during the
applicable royalty payment period in the country in which the sale of the
Combination

 

-7-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

Product was made. Where the other active ingredients are sold separately in
finished form but the Product is not, Net Sales for the Product shall be
determined by multiplying actual Net Sales of the Combination Product
(determined by reference to the definition of Net Sales set forth above) during
the royalty payment period by the difference obtained by subtracting from one
(1) the ratio of the average per-unit sale price of products containing only the
other active ingredient when sold separately in finished form to the average
per-unit Net Sales of the Combination Product, in each case during the
applicable royalty reporting period in the country in which the sale of the
Combination Product was made. In the event that such average sales price cannot
be determined for either of the Product or for products containing only the
other active ingredient included in the Combination Product, Net Sales for
purposes of determining payments under this Agreement shall be determined by
good faith negotiations between the Parties.

1.26. “Patent Rights” shall mean all patents and patent applications in any
country in the world, including any continuations, continuations-in-part,
divisionals, provisionals or any substitute applications, any patent issued with
respect to any such patent applications, any reissue, reexamination, renewal or
extension (including any supplemental protection certificate) of any such
patent, and any confirmation patent or registration patent or patent of addition
based on any such patent, and all non-United States counterparts of any of the
foregoing.

1.27. “[ * ] Target” shall mean human [ * ].

1.28. “Person” shall mean any natural person, corporation, general partnership,
limited partnership, joint venture, proprietorship or other business
organization or a Governmental Authority.

1.29. “Phase I” shall mean human clinical trials, the principal purpose of which
is the preliminary evaluation of safety in healthy individuals as more fully
defined in 21 C.F.R. §312.21(a) or similar clinical study in a country other
than the United States. An initial study in patients where the primary purpose
is the preliminary evaluation of safety will be considered a Phase I study.

1.30. “Phase II” shall mean human clinical trials conducted on a limited number
of patients for the primary purpose of evaluation of both clinical efficacy and
safety, or to obtain a preliminary evaluation of the dosage regimen, as more
fully defined in 21 C.F.R. §312.21(b).

1.31. “Phase III” shall mean human clinical trials, the principal purpose of
which is to establish substantial evidence of both safety and efficacy in
patients with the disease or condition being studied, as more fully defined in
21 C.F.R. §312.21(c) or similar clinical study in a country other than the
United States. Phase III shall also include any other human clinical trial
intended to serve as a pivotal trial to support the submission of an application
for regulatory approval.

1.32. “Product” shall mean a Licensed Product or Reverted Licensed Product, as
applicable.

1.33. “Raf Target” shall mean the human Raf protein together with the Raf
protein family members [ * ].

 

-8-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

1.34. “Regulatory Approval” shall mean approval of the health regulatory agency
in a country (FDA in the U.S. and comparable authority outside the U.S.)
necessary for the marketing and sale of a product in the applicable country. As
used herein, “Regulatory Approval” shall not include pricing or reimbursement
approval.

1.35. “Research Program” shall mean the activities undertaken by Sunesis and
Biogen Idec pursuant to the Original Agreement during the Research Term.

1.36. “Research Term” shall mean the period of time beginning on the Original
Agreement Effective Date and ending on June 30, 2008.

1.37. “Reverted Compound” shall mean, with respect to a Reverted Licensed
Product, any Licensed Compound included in such Reverted Licensed Product.

1.38. “Sales Returns and Allowances” shall mean, with respect to a specific
Product, the sum of (a) and (b), where: (a) is a provision, determined by a
Party under U.S. GAAP for sales of such Product for (i) trade, cash and quantity
discounts on such Product (other than price discounts granted at the time of
invoicing and which are already included in the determination of Gross Sales),
(ii) credits or allowances given or made for rejection or return of, and for
uncollectable amounts on, previously sold product or for rebates or retroactive
price reductions (including Medicare, Medicaid and similar types of rebates and
chargebacks), (iii) taxes, duties or other governmental charges levied on or
measured by the billing amount for such Product, as adjusted for rebates and
refunds (excluding income and franchise taxes), (iv) charges for freight and
insurance directly related to the distribution of such Product, to the extent
included in Gross Sales, and (v) credits for allowances given or made for
wastage replacement, indigent patient and any other sales programs agreed to by
the Parties for such Product; and (b) is a periodic adjustment of the provision
determined in (a) to reflect amounts actually incurred by a Party for items (i),
(ii), (iii), (iv) and (v) in clause (a).

1.39. “Sublicensee” shall mean a Third Party expressly licensed by a Party or
its Affiliate to make, use, import, offer for sale or sell a Product. The term
“Sublicensee” shall not include distributors (i.e., a Third Party who purchases
Product from a Party for resale).

1.40. “Sunesis Collaboration Technology” shall mean all Sunesis Collaboration
Patents and Sunesis Collaboration Know-How.

1.40.1 “Sunesis Collaboration Patents” shall mean (a) those Patent Rights set
forth on Exhibit 1.4, the subject of which is an invention: (i) conceived in the
course of performing the Research Program during the Research Term and reduced
to practice prior to the Effective Date solely by or under authority of
personnel of Sunesis or any of its controlled Affiliates or (ii) conceived and
reduced to practice solely by or under authority of personnel of Sunesis or any
of its controlled Affiliates after the Original Agreement Effective Date but
prior to the Effective Date, in the case of either (i) or (ii) in the course of
activities [ * ] to the Designated Targets or to the discovery, research, or
development of Licensed Compounds or Licensed Products; and (b) all Patent
Rights that arise during the Term that claim or cover any Sunesis Collaboration
Know-How. Notwithstanding the foregoing, Sunesis Collaboration

 

-9-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

Patents shall in all cases exclude Sunesis Core Technology and Joint
Sunesis-Biogen Collaboration Patents.

1.40.2 “Sunesis Collaboration Know-How” shall mean any Know-How: (i) made or
developed solely by or under authority of personnel of Sunesis or any of its
controlled Affiliates in the course of performing the Research Program during
the Research Term; or (ii) made or developed solely by or under authority of
personnel of Sunesis or any of its controlled Affiliates after the Original
Agreement Effective Date but prior to the Effective Date, in the case of either
(i) or (ii) in the course of activities [ * ] to the Designated Targets or to
the discovery, research, or development of Licensed Compounds or Licensed
Products. Notwithstanding the foregoing, Sunesis Collaboration Know-How shall in
all cases exclude Sunesis Core Technology, Joint Sunesis-Biogen Collaboration
Know-How and Excluded Compounds (as defined in the Original Agreement).

1.41. “Sunesis Core Technology” shall mean all Patent Rights (all as listed on
Exhibit 1.41) and all information, materials and other subject matter, and
improvements thereof, relating to (i) mutants or the use thereof in screening,
(ii) the use of novel protein engineering techniques and their application in
drug discovery, (iii) target-directed fragment discovery and maturation to
produce drug leads, including monophores, extenders and fragments and monophore,
extender and fragment libraries for such purposes, or (iv) covalent tethering
and techniques related thereto (e.g., NMR, X-ray, mass spec. AUC, Biacore) and
its use to discover fragments and test binding hypotheses of fragments and
leads: (a) Controlled by Sunesis or its controlled Affiliates prior to the
Original Agreement Effective Date or during the Research Term; or (b) made by
Biogen Idec in the course of activities directed to the discovery, research, or
development of Licensed Compounds; provided, in the case of (b) that such item
was made using or derived from Sunesis Core Technology.

1.42. “Sunesis Licensed Technology” shall mean Sunesis Licensed Patents and
Sunesis Licensed Know-How.

1.42.1 “Sunesis Licensed Patents” shall mean (i) Sunesis’s interest in
Collaboration Patents, (ii) the Patent Rights Controlled by Sunesis as of the
Effective Date that claim or cover the Designated Targets, Licensed Compounds or
Licensed Products, and (iii) all Patent Rights that arise during the Term that
claim or cover any Know-How Controlled by Sunesis as of the Effective Date that
relates to a Designated Target, Licensed Compound or Licensed Product.

1.42.2 “Sunesis Licensed Know-How” shall mean (i) Sunesis Collaboration
Know-How, (ii) Sunesis’s interest in Joint Sunesis-Biogen Collaboration Know-How
and Biogen Idec Collaboration Know-How, and (iii) any Know-How Controlled by
Sunesis as of the Effective Date that relates to a Designated Target, Licensed
Compound or Licensed Product.

1.43. “Synthesize”, “Synthesis” or “Synthesized” shall mean, with respect to a
chemical composition, the act of (i) first physical synthesis of such chemical
composition, or (ii) if such composition had previously been first actually
synthesized, first physically establishing, in a

 

-10-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

relevant assay, that such composition is Target Selective against a specific
Designated Target. For avoidance of doubt Synthesize shall not include chemical
compositions synthesized in vivo.

1.44. “Target Selective” shall mean, when used to describe a chemical compound
with respect to a specified Designated Target, that such compound exhibits [ * ]
cell-based assay, and [ * ] (i) [ * ] enzyme assay [ * ] or (ii) [ * ]. For the
purposes of the foregoing, the relevant cell-based and enzyme assays shall be as
specified in Exhibit 1.44, and the [ * ] in (ii) shall be measured in the same
enzyme assay as (i).

1.45. “Third Party” shall mean any person or entity other than Sunesis and
Millennium, and their respective Affiliates.

1.46. “Valid Claim” shall mean [ * ]

1.47. Additional Terms. In addition to the foregoing, the following terms shall
have the meaning defined in the corresponding Section below:

 

Term

 

Section

Defined

 

Term

 

Section

Defined

Agreement   Preamble   Key Subsidiary   2.2.4(a) Annual Net Sales   6.3.1  
Liabilities   12.1 Biogen Idec   Background   Licensed Compound Joint Technology
  9.1.1(c) Change in Control   2.2.4(a)   Licensed Product Team   2.3
Co-Development Plan and Budget   2.2.2   Millennium   Preamble Co-Funded Product
  2.2.1   Millennium-Biogen Agreement   Background Co-Funded Territory   2.2.1  
Millennium Competitor   2.2.4(b) Co-Funding Percentage   2.2.3   New
Sunesis-Biogen Agreement   Background [ * ]   15.3   Notice Period   2.2.1
Controlling Party   9.3.4   Original Agreement   Background Cooperating Party  
9.3.4   Original Agreement Effective Date   Background Co-Promoted Licensed
Product   3.2   Other Joint Technology   9.1.1(c) Co-Promotion Option   3.2  
Other Millennium Technology   5.1.3

 

-11-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

Term

 

Section

Defined

 

Term

 

Section

Defined

Election Notice   2.2.1   Party, Parties   Preamble Election Percentage   3.2.1
  Phase II Drug Collaboration   5.3 Indemnitee   12.3   Phase II Notice   2.2.1
Indemnitor   12.3   post Phase I Development Costs   2.2.4(c) Indication  
6.2.2(b)   Projected Start Date   2.2.1 Initial Development Plan   2.2.1   Raf
Patents   9.1.1(a) Initial Territory   2.2   Reverted Licensed Product   8.2
Infringement Action   9.3.4   Sales and Marketing Plan   4.4.2 JCC   4.4.1  
Sunesis   Preamble JDC   4.3.1   Subject Infringement   9.3.1 Joint Steering
Committee   4.1   Term   13.1 Joint Sub-Committee   4.2   Three Party Agreement
  Background

1.48. Construction. In construing this Agreement, unless expressly specified
otherwise:

1.48.1 references to Sections, Articles and Exhibits are to sections and
articles of, and exhibits to, this Agreement;

1.48.2 except where the context otherwise requires, use of any gender includes
any other gender, and use of the singular includes the plural and vice versa;

1.48.3 any list or examples following the word “including” shall be interpreted
without limitation to the generality of the preceding words;

1.48.4 except where the context otherwise requires, the word “or” is used in the
inclusive sense; and

1.48.5 all references to “dollars” or “$” herein shall mean U.S. Dollars.

 

-12-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

ARTICLE 2

PRODUCT DEVELOPMENT

2.1. Development by Millennium. Commencing on the Effective Date, Millennium
shall be responsible for undertaking a development program aimed at ultimately
seeking Regulatory Approval for Licensed Products.

2.2. Co-Funding Option. Sunesis shall have the right, on a Licensed
Product-by-Licensed Product basis, to elect to fund a portion of post Phase I
Development Costs of a Licensed Product in all countries worldwide other than
Japan (the “Initial Territory”); provided, however, that Sunesis shall not have
the Co-Funding Option with respect to any Licensed Product directed against a
Designated Target for which Sunesis has entered into a Phase II Drug
Collaboration. In the event that Sunesis elects to exercise its Co-Funding
Option with respect to the Initial Territory for a particular Licensed Product
pursuant to the preceding sentence, then Sunesis shall have the right to elect
to fund a portion of post Phase I Development Costs of such Licensed Product in
Japan, all in accordance with this Section 2.2.

2.2.1 Election. For so long as Sunesis continues to have a Co-Funding Option for
a Licensed Product, Millennium shall notify Sunesis [ * ] for each Licensed
Product in each of the applicable territories described above in Section 2.2
where the primary endpoint of such trial involves a preliminary determination of
efficacy. Such notice shall include the date [ * ] Sunesis may elect, by so
notifying Millennium in writing [ * ] (the “Notice Period”), to participate in
funding the further development of such Licensed Product in the applicable
territory, as described in this Section 2.2 (such notice, the “Election
Notice”). [ * ] until the end of the Notice Period, Millennium shall cooperate
fully with Sunesis, and shall promptly provide Sunesis with access to such
material information, to the extent such information is not included in the
Initial Development Plan or otherwise has not been communicated previously to
Sunesis, as Sunesis may reasonably request to enable Sunesis to make an informed
decision whether to exercise its Co-Funding Option under this Section 2.2 with
respect to such Licensed Product. Such cooperation shall include consulting with
Sunesis in good faith regarding the Initial Development Plan, and the financial,
scientific and regulatory assumptions reflected therein. In the event Sunesis
exercises its Co-Funding Option with respect to a particular Licensed Product
(such Licensed Product, a “Co-Funded Product”), the provisions of Sections 2.2.2
through 2.2.4 below shall apply with respect to such Co-Funded Product in the
Co-Funded Territory. The “Co-Funded Territory” shall consist of the Initial
Territory for each Co-Funded Product, and in the event Sunesis elects to
exercise its Co-Funding Option for Japan with respect to a particular Co-Funded
Product, the Co-Funded Territory shall mean all territories worldwide for such
Co-Funded Product. In the event that Sunesis elects not to exercise the
Co-Funding Option with respect to a Licensed Product or fails to provide an
Election Notice within the applicable Notice Period, Sunesis shall no longer
have the right to exercise the Co-Funding Option, and Millennium shall have no
further obligations under this Section 2.2.1, with respect to such Licensed
Product.

2.2.2 JDC. For each Co-Funded Product, the Parties shall establish and maintain
a JDC in accordance with Section 4.3 below, which shall be responsible for
establishing

 

-13-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

the plan and budget for the development of each Co-Funded Product (each, a
“Co-Development Plan and Budget”) and overseeing the implementation of such
plan. Such Co-Development Plan and Budget shall be comprehensive (as of the time
of preparation and delivery hereunder) and shall fully describe at least the
proposed activities and data related to [ * ], and other activities and
timelines directed to obtaining the initial and subsequent Regulatory Approvals
in each applicable country. Unless otherwise specified in a Co-Development Plan
and Budget amounts reflected for a full year shall be deemed budgeted in equal
amounts for each calendar quarter of such year.

2.2.3 Co-Funding Obligation. In the event Sunesis exercises its Co-Funding
Option with respect to a Licensed Product, Sunesis shall be obligated to
reimburse Millennium for a percentage (the “Co-Funding Percentage”) of post
Phase I Development Costs for such Licensed Product, subject to the provisions
of this Section 2.2. It is understood and agreed that the Co-Funding Percentage
shall initially be [ * ] percent ([ * ]%) for each Co-Funded Product. In
addition the following shall apply:

(a) The Co-Development Plan and Budget will be updated on a quarterly basis.
Millennium shall provide to Sunesis its then current estimates for each upcoming
budget year for each Co-Funded Product by November 15 of each year. Promptly
following April 1 of each calendar year during the development activities for a
particular Co-Funded Product or such other date as is mutually agreed by the
Parties, the JDC shall update and amend the Co-Development Plan and Budget for
such Co-Funded Product for the period ending March 31 of the subsequent calendar
year. Millennium shall provide Sunesis with reasonable opportunity to provide
input into each Co-Development Plan and Budget, and, subject to Article 4,
Millennium shall reasonably consider Sunesis’s comments in establishing and
updating each Co-Development Plan and Budget.

(b) Within thirty (30) days after the end of each calendar quarter, Millennium
shall provide to Sunesis a statement reflecting the total post Phase I
Development Costs incurred by Millennium in accordance with the then-current
Co-Development Plan and Budget during such calendar quarter with respect to each
Co-Funded Product. Within thirty (30) days after Sunesis’s receipt of such
statement, Sunesis shall reimburse Millennium for the applicable Co-Funding
Percentage of the post Phase I Development Costs incurred by Millennium during
such calendar quarter for such Co-Funded Product.

(c) Upon [ * ] days written notice to Millennium, Sunesis may terminate its
Co-Funding Option for a particular Co-Funded Product. In such event, Sunesis’s
funding obligation under this Section 2.2.3 above shall apply only with respect
to post Phase I Development Costs for activities conducted with respect to such
Co-Funded Product prior to the effective date of such termination. Should
Sunesis terminate its Co-Funding Option under this Section 2.2.3(c) with respect
to a particular Co-Funded Product, (i) any royalties payable to Sunesis on such
Co-Funded Product shall be paid in accordance with Section 6.3.1, subject to
Section 6.3.2(b), and (ii) Sunesis shall relinquish its right to participate in
the JDC pursuant to Section 4.3 and any right to its Co-Promotion Option under
Section 3.2 for such Co-Funded Product.

 

-14-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

(d) Upon written notice to Millennium at least ninety (90) days prior to the end
of a budget year, Sunesis may elect to [ * ], by so notifying Millennium in
writing, referencing this Section 2.2.3(d) and specifying [ * ]. In such event,
Sunesis shall receive a [ * ] in accordance with the schedule set forth in
Section 6.3.2(c) below [ * ]. Upon such election, Sunesis’s previous Co-Funding
Percentage under this Section 2.2.3 shall apply only with respect to post Phase
I Development Costs for activities conducted with respect to such Co-Funded
Product [ * ] with respect to such Co-Funded Product. Sunesis may [ * ] provided
that (i) Sunesis shall not be permitted [ * ] its Co-Funding Percentage for such
Co-Funded Product, and (ii) Sunesis may [ * ]. As used herein, “budget year”
shall mean April 1 through March 31, provided that Millennium shall have the
right to change the budget year to coincide with Millennium’s annual budget
cycle, provided that Millennium provides Sunesis with at least one hundred
twenty (120) days notice of such change.

(e) Notwithstanding the foregoing, in the event that Sunesis experiences a
Change in Control, then Sunesis’s Co-Promotion rights under Section 3.2, the
right to participate in the JDC under Section 4.3, the right to participate in
the JCC under Section 4.4, and any Licensed Product Teams under Section 2.3
shall terminate. In addition:

(i) With respect to any Co-Funded Product for which Sunesis has exercised its
Co-Funding Option prior to such Change of Control, Sunesis’s rights and
obligations under this Section 2.2.3 shall continue, provided that Millennium
shall no longer be obligated to provide the detailed plans required of a
Co-Development Plan and Budget to Sunesis (or its successor entity), but shall
provide Sunesis (or its successor entity) with annual budgets of post Phase I
Development Costs for such Co-Funded Product.

(ii) Sunesis’s Co-Funding Option with respect to future Licensed Products shall
continue as well (i.e., with respect to Licensed Products that are not Co-Funded
Products as of the date of such Change of Control), provided that Millennium
shall no longer be obligated to provide for each Licensed Product the detailed
plans and clinical data required of an Initial Development Plan and Phase II
Notice. Millennium shall, however, provide Sunesis (or its successor entity)
with annual budgets of post Phase I Development Costs for such Co-Funded Product
in accordance with the timetable for a Phase II Notice set forth in
Section 2.2.1, and shall provide reasonable cooperation to Sunesis (or its
successor entity) in evaluating such Licensed Product and the post Phase I
Development Costs related thereto, including consulting with Sunesis (or its
successor entity) in good faith regarding such annual budgets and the financial,
scientific and regulatory assumptions reflected therein.

2.2.4 Certain Terms. As used in this Section 2.2, the following terms shall have
the meanings set forth below:

(a) “Change in Control” shall mean, [ * ]

(b) “Millennium Competitor” shall mean [ * ]

(c) “post Phase I Development Costs” shall mean, with respect to a particular
Co-Funded Product, the Development Costs incurred by Millennium or its
Affiliates

 

-15-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

following Sunesis’s exercise of the Co-Funding Option for such Co-Funded Product
in the Co-Funded Territory for such Co-Funded Product. For the avoidance of
doubt, (i) post Phase I Development Costs shall not include any Development
Costs incurred by Millennium or its Affiliates for any subsequent Phase I
trials, and (ii) Development Costs relating to activities directed at obtaining
Regulatory Approval in Japan for a Co-Funded Product shall not be considered
post Phase I Development Costs to the extent such Development Costs are incurred
(A) prior to completion of the Phase I trials for such Co-Funded Product in
Japan, or (B) if no Phase I trials are necessary or performed for such Co-Funded
Product in Japan, then prior to initiation of any clinical trial other than a
Phase I trial.

2.3. Licensed Product Team. Upon identification of a Development Candidate for
any Licensed Compound other than BIIB024, the Parties shall form a product team
with respect to such Licensed Compound (which team shall report to the JDC if
Sunesis exercises its Co-Funding Option with respect to such Licensed Compound),
comprised of Millennium and Sunesis personnel, that will share all relevant
information and implement the further development and regulatory affairs with
respect to that Co-Funded Product (each a “Licensed Product Team”) in accordance
with the Co-Development Plan and Budget. It is understood that both Millennium
and Sunesis shall have the opportunity for meaningful participation in the
activities of a Licensed Product Team commensurate with their respective levels
of funding participation; it being further understood that Millennium shall
control the Development of the Licensed Product. Sunesis shall be notified at
least two weeks in advance of the date of each Licensed Product Team meeting,
which meetings shall be held quarterly by in-person meetings or electronic
conference, and shall have the opportunity to have its representatives attend
such meeting. Millennium shall provide such Sunesis representatives with all
information distributed to Millennium members of the Licensed Product Team, and
such other material information as Sunesis may reasonably request from time to
time. With respect to [ * ], within thirty (30) days after the Effective Date,
the Parties shall establish a Licensed Product Team for [ * ] as a Licensed
Product (i.e., even though the such Licensed Product is not yet a Co-Funded
Product). The Parties shall maintain any such Licensed Product Team under this
Section 2.3 until the Co-Funding Option lapses or is declined with respect to
such Licensed Product. For clarity, it is understood that the establishment of a
Licensed Product Team hereunder for a Licensed Product directed at the Raf
Target or the [ * ] Target shall not obligate Sunesis to subsequently exercise
the Co-Funding Option with respect to such Licensed Product. The Licensed
Product Team will be composed of three (3) representatives of Millennium (at
Millennium’s discretion) and three (3) representatives of Sunesis, who shall be
appointed (and may be replaced at any time) by the respective Party on written
notice to the other Party in accordance with this Agreement. The Parties may
invite additional employee observers based on the subject matter of the meeting,
who shall be able to participate in such meetings. The Sunesis representatives
shall not be entitled to vote on any Licensed Product Team matters. In any
event, the Licensed Product Team shall terminate in the event that Sunesis does
not exercise its Co-Funding Option.

2.4. Regulatory Matters. Millennium shall file and be the owner of all
regulatory filings for Licensed Compounds or Licensed Products (including
Co-Funded Products) developed pursuant to this Agreement, including all NDAs and
Regulatory Approvals, unless otherwise agreed by the Parties.

 

-16-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

2.5. Records; Inspections.

2.5.1 Research Records. Sunesis shall maintain records of the Research Program
relating to the Licensed Compounds and Designated Targets (or cause such records
to be maintained) in sufficient detail and in good scientific manner as will
properly reflect all work done and results achieved in such performance of the
Research Program.

2.5.2 Inspections. During the one-year period following the Effective Date,
Sunesis shall provide Millennium with access to the records referred to in
Section 2.5.1, upon reasonable request, during ordinary business hours and
subject to appropriate confidentiality agreement in the event that Third Party
confidential information is involved.

ARTICLE 3

PRODUCT COMMERCIALIZATION

3.1. Commercialization Rights. Subject to the provisions of Section 3.2,
Millennium shall be responsible for the establishment and implementation of the
strategy, plans and budgets for marketing and promotion of the Licensed
Products.

3.2. Co-Promotion Option. Sunesis will have an option (the “Co-Promotion
Option”) to co-promote each Co-Funded Product in the Co-Funding Territory,
according to the terms and conditions set forth in this Section 3.2. This
Co-Promotion Option may be exercised at Sunesis’s discretion on a Co-Funded
Product-by-Co-Funded Product and country-by-country basis for any Co-Funded
Product, by so notifying Millennium in writing within [ * ] for such Co-Funded
Product in such country (each such Co-Funded Product for which Sunesis exercises
the Co-Promotion Option being referred to as a “Co-Promoted Licensed Product”).
[ * ] Millennium shall provide Sunesis with a good faith estimate of the number
of field force personnel to be deployed for such Co-Funded Product in the
applicable territory for [ * ], together with a then-current Sales and Marketing
Plan for such Co-Funded Product. The estimate of the number of field force
personnel to be deployed shall be prepared by the JCC, and shall take into
consideration the then-current marketing and promotion practices in the relevant
markets and the number and nature of other products, if any, including the
detail position, if applicable, that such field force personnel will be selling.
In situations where field force personnel will be selling multiple products, the
JCC shall make a good faith allocation of the field force personnel’s time to be
spent on each product. In the event that Sunesis elects not to exercise the
Co-Promotion Option with respect to a Co-Funded Product or fails to notify
Millennium in writing of its election within the applicable [ * ] in any
country, Sunesis shall no longer have the right to exercise the Co-Promotion
Option with respect to such Co-Funded Product in such country.

As used in this Agreement, “co-promote” or “co-promotion” shall mean to promote
jointly or joint promotion of a Licensed Product through Millennium’s and
Sunesis’s respective sales forces under the same brand name, with Millennium
booking all sales of such Co-Promoted Licensed Product, all as shall be more
specifically set forth in a co-promotion agreement for each of the countries in
which Sunesis co-promotes, such agreement to be negotiated in good faith as soon
as practicable following the exercise by Sunesis of the Co-Promotion Option for
a Co-Promoted Licensed Product and reflecting the terms set forth in this
Article 3 and other

 

-17-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

customary terms and provisions. A co-promotion agreement shall include the
following provisions: (a) Sunesis shall, within thirty (30) days of the end of
each calendar quarter, send a written report to Millennium setting out for each
applicable country and each Co-Promoted Licensed Product, the number of field
sales force representatives performing co-promotion activities hereunder, and
the number and nature of other products, if any, that such field force personnel
promoted during such calendar quarter. (b) In the event that [ * ] that are
allocated to Sunesis in the applicable Sales and Marketing Plan, Millennium may
terminate Sunesis’s right to co-promote such Co-Promoted Licensed Product in
such country upon written notice to Sunesis.

3.2.1 Scope and Coordination of Co-Promotion. Upon exercise of its Co-Promotion
Option with respect to a Co-Promoted Licensed Product, Sunesis shall have the
right to field [ * ] (the “Election Percentage”) of the field force efforts, as
such field force is determined in good faith by the JCC, with respect to the
Co-Promoted Licensed Product in the applicable country. The JCC shall be
responsible for coordinating the co-promotion activities under this Section 3.2,
and shall develop the strategies and programs to optimally carry out marketing
and promotional activities, including the assignment of sales force
responsibilities in accordance with the Sales and Marketing Plan. It is
understood that Sunesis may use one or more contract service organizations for
its activities under this Section 3.2, provided that with respect to each
Co-Promoted Licensed Product, Sunesis [ * ] for such Co-Promoted Licensed
Product. Sunesis field sales force representatives will be employed by Sunesis
and Sunesis shall be responsible for the payment of all such representatives’
salary, out-of pocket expenses (other than for promotional materials), bonus
(Sunesis shall adopt reasonable bonus plans/systems to reward sales of the
Co-Promoted Licensed Product) and benefits, pension, insurance, social security
and any other related obligations.

3.2.2 Co-Promotion Obligations. Sunesis shall employ a professional and trained
sales force to co-promote the Co-Promoted Licensed Product, and such sales force
shall meet standards of competence and professionalism as are common in the
pharmaceutical industry. In all events, Sunesis’s co-promotion shall be
conducted as directed by the JCC and in accordance with the then current Sales
and Marketing Plan and in accordance with all applicable laws. Millennium shall
provide to Sunesis’s sales personnel [ * ] any Co-Promoted Licensed
Product-specific training and promotional materials (including samples), and
shall permit Sunesis’s sales personnel to attend and participate in any
Co-Promoted Licensed Product-specific seminars and sales training programs [ * ]
Sunesis, in each case as reasonably necessary to effectively promote the
particular Co-Promoted Licensed Product consistent with the Sales and Marketing
Plan.

3.2.3 Reimbursement. For the performance of the obligations of Sunesis under
this Section 3.2 and the co-promotion agreement, Millennium shall reimburse
Sunesis as described herein. [ * ]. In the event that Sunesis sales
representatives promote any other products other than such Co-Promoted Licensed
Product, then Millennium shall only reimburse Sunesis for the pro rata share of
the cost of such Sunesis sales representatives.

3.2.4 Right to Terminate Co-Promotion. Sunesis shall have the right, on a
territory-by-territory basis, to terminate its co-promotion of any Co-Promoted
Licensed Product,

 

-18-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

and its obligations under this Section 3.2 with respect to such Co-Promoted
Licensed Product, on a Co-Promoted Licensed Product-by-Co-Promoted Licensed
Product basis, upon [ * ] prior written notice to Millennium. Millennium shall
have the right, on a country-by-country basis, to terminate Sunesis’s
co-promotion of any Co-Promoted Licensed Product, and Millennium’s obligations
under this Section 3.2 with respect to such Co-Promoted Licensed Product, on a
Co-Promoted Licensed Product-by-Co-Promoted Licensed Product basis, (a) [ * ]
after written notice to Sunesis following any material breach of any applicable
law, rule or regulation with respect to the co-promotion of such Co-Promoted
Licensed Product, or (b) [ * ] after written notice to Sunesis following any
other material breach by Sunesis relating to the co-promotion of such
Co-Promoted Licensed Product in such country if Sunesis does not cure such
breach within the applicable specified cure period in Section 3.2.4(a) or (b).
Upon termination of co-promotion under this Section 3.2.4 or the co-promotion
agreement, Sunesis shall have no right to reimbursement by Millennium under
Section 3.2.3 for services provided in the applicable country after the
effective date of such termination.

3.3. Amendment of Sales and Marketing Plan. Promptly upon exercise of Sunesis’s
Co-Promotion Option hereunder, the JCC shall meet to revise the Sales and
Marketing Plan to reflect the sales activities to be undertaken by Sunesis,
including the formulation of a mechanism to establish and adjust cost
allocation, and the definition of a relevant field sales force promotional
activity metric for purposes of allocating the activities of sales
representatives.

3.4. Sunesis [ * ]. To the extent consistent with applicable law, the [ * ]
Sunesis shall [ * ], on all [ * ] for all [ * ] Licensed Products in the
applicable country.

3.5. Sunesis Insurance. In the event that Sunesis exercises its Co-Promotion
Option, Sunesis shall procure and continue to maintain, at its own cost, the
following insurance coverage: Commercial General Liability, including coverage
for products and completed operations (maintained for a period of at least five
(5) years after expiration or termination of this Agreement) and contractual
liability (including coverage for advertising and personal injury). The JCC
shall set commercially reasonable and appropriate minimum terms and conditions
for such insurance coverage, consistent with then-current pharmaceutical
industry practice for commercialization efforts of similar scope to the
co-promotion activities undertaken hereunder. Sunesis shall provide Millennium
with a certificate of insurance reflecting such coverage.

ARTICLE 4

MANAGEMENT

4.1. Joint Steering Committee. Within thirty (30) days of the Effective Date,
the Parties shall establish a joint steering committee (“Joint Steering
Committee”) to provide oversight and management of the activities undertaken
under this Agreement. The Joint Steering Committee will be composed of two
(2) representatives of each Party who shall be appointed (and may be replaced at
any time) by such Party on prior written notice to the other Party in accordance
with this Agreement. At least one (1) representative of a Party on the Joint
Steering Committee shall be a vice president or more senior officer of such
Party, and the representatives

 

-19-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

shall have relevant experience and expertise in research, development and
commercialization of biopharmaceuticals.

4.1.1 Responsibilities. The Joint Steering Committee shall be responsible for
(i) reviewing the efforts of the JDC in the conduct of ongoing development
activities and regulatory affairs with respect to Co-Funded Products under
Article 2, and resolving disputes as to matters to be decided by the JDC under
this Agreement; (ii) reviewing the efforts of the JCC in the conduct of
promotional activities of the Parties with respect to Co-Promoted Licensed
Products under Article 3, and resolving disputes as to matters to be decided by
the JCC under this Agreement; and (iii) taking such other actions as are
specifically allocated to the Joint Steering Committee under this Agreement.

4.1.2 Meetings. The Joint Steering Committee shall meet quarterly, or at such
frequency as agreed by the respective committee members. Meetings of the Joint
Steering Committee shall be at such locations as the Parties agree, and will
otherwise communicate regularly by telephone, electronic mail, facsimile or
video conference. With the consent of the Parties, other representatives of
Sunesis or Millennium may attend the Joint Steering Committee meetings as
nonvoting observers based on the subject matter of the meeting.

4.1.3 Decisions. Any approval, determination or other action of the Joint
Steering Committee shall require agreement of the members of the Joint Steering
Committee, with each Party having one (1) vote. Action that may be taken at a
meeting of the Joint Steering Committee also may be taken without a meeting if a
written consent setting forth the action so taken is signed by all members of
the Joint Steering Committee.

4.1.4 Disputes. In the event the Joint Steering Committee is unable to reach
consensus on a particular matter within its jurisdiction or that of the JDC or
JCC, the matter shall be referred to executives of the Parties in accordance
with Section 14.1, and if such referral does not resolve such matter, then
Millennium shall have the right to cast a deciding vote on the JSC.
Notwithstanding the foregoing, Millennium shall not have the right to exercise [
* ] of this Agreement or that [ * ] Sunesis. In the evaluation of a Diligence
Summary pursuant to Section 8.5, any decision of the JSC shall be binding on the
Parties, but in the event the JSC is unable achieve agreement with respect to
such evaluation, then such dispute shall be resolved as set forth in
Section 8.5.

4.2. Joint Sub-Committees. The Parties shall form the JDC and JCC (each, a
“Joint Sub-Committee”) in accordance with the terms set forth in Sections 4.3
and 4.4.

4.2.1 Generally. Each Joint Sub-Committee shall meet at such locations as the
Parties agree, and will otherwise communicate regularly by telephone, electronic
mail, facsimile or video conference. Each Party shall be responsible for all of
its own expenses associated with attendance of such meetings, and either Party
may replace its respective representatives to each Joint Sub-Committee at any
time, with prior written notice to the other Party. Other representatives of
Sunesis or Millennium may attend the Joint Sub-Committee meetings as nonvoting
observers based on the subject matter of the meeting. From time to time, each
Joint

 

-20-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

Sub-Committee may establish further subcommittees to oversee particular projects
or activities, and such further subcommittees will be constituted as such Joint
Sub-Committee approves.

4.2.2 Decision Making. Decisions of each Joint Sub-Committee shall be made by
unanimous approval of the team leaders from each Party present in person or by
other means (e.g., teleconference) at any meeting; provided that at least one
member from each Party must be so present and voting. In the event that
unanimity is not achieved within a Joint Sub-Committee on a decision required to
be made by such Joint Sub-Committee, the matter will be referred to the Joint
Steering Committee, which in each case shall promptly meet and endeavor in good
faith to resolve such matter in a timely manner. In the event the Joint Steering
Committee is unable to reach consensus on a particular matter, such matter shall
be resolved in accordance with Section 4.1.4 above.

4.3. Joint Development Committee.

4.3.1 Formation. Promptly following notice from Sunesis that it is exercising
its Co-Funding Option, the Parties shall establish a Joint Development Committee
(“JDC”) with respect to the development of the applicable Co-Funded Product. The
JDC will be composed of three (3) representatives of Millennium (at Millennium’s
discretion) and three (3) representative of Sunesis who shall be appointed (and
may be replaced at any time) by the respective Party on written notice to the
other Party in accordance with this Agreement. In the event that Sunesis
undergoes a Change of Control (as that term is defined in Section 2.2.4(a)
above), the JDC shall be dissolved in accordance with Section 2.2.3(e).

4.3.2 Responsibilities. The responsibilities of the JDC shall consist of
(i) overseeing the ongoing development of Co-Funded Product(s),
(ii) establishing Co-Development Plans and Budgets for Co-Funded Products,
(iii) monitoring and approving development activities under such Co-Development
Plans and Budgets, (iv) reviewing and approving regulatory correspondence, final
study reports and submissions to Regulatory Authorities relating to Co-Funded
Products, and (v) making such decisions as are expressly provided in Article 2.

4.3.3 Meetings and Information. The JDC shall meet at least quarterly.
Millennium shall notify Sunesis at least two weeks in advance of the date of
each JDC meeting.

4.4. Joint Commercialization Committee.

4.4.1 Formation. Upon request by either Party following [ * ] for a Co-Funded
Product and the election to co-promote by Sunesis, the Parties shall establish a
Joint Commercialization Committee (“JCC”) with respect to commercialization of
such Co-Funded Product(s). The JCC will be composed of three (3) representatives
of Millennium (at Millennium’s discretion) and three (3) representative of
Sunesis who shall be appointed (and may be replaced at any time) by the
respective Party on written notice to the other Party in accordance with this
Agreement. In any event, the JCC shall terminate upon the expiration of all
Co-Promotion Options or termination of all co-promotion by Sunesis.

 

-21-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

4.4.2 Responsibilities. The JCC shall have responsibility to monitor the conduct
and progress of the commercialization strategy, plans, and budgets, including
establishment of a plan and budget for the marketing, promotion, sale and
distribution of such Co-Funded Product (each a “Sales and Marketing Plan”) and
managing the promotional activities of the Parties with respect to Co-Promoted
Licensed Products under Article 3 above. The JCC shall update the Sales and
Marketing Plan periodically, and no less often than annually, and shall include
therein detailed plans and budgets for the marketing, promotion, sale and
distribution of each Co-Funded Product.

4.4.3 Meetings and Information. The JCC shall meet at least quarterly.
Millennium shall notify Sunesis at least two weeks in advance of the date of
each JCC meeting.

ARTICLE 5

LICENSES

5.1. Development and Commercialization Licenses.

5.1.1 License under the Sunesis Licensed Technology to Licensed Products.
Subject to the terms and conditions of this Agreement, Sunesis hereby grants to
Millennium a worldwide, exclusive license under the Sunesis Licensed Technology,
with the right to grant and authorize sublicenses as provided in Section 5.2, to
Develop, make, have made, use, import, offer for sale, sell and otherwise
exploit Licensed Compounds and Licensed Products in the Field.

5.1.2 License under the Sunesis Core Technology to Licensed Products. Subject to
the terms and conditions of this Agreement, Sunesis hereby grants to Millennium
a worldwide, non-exclusive license under the Sunesis Core Technology to make,
have made, use, import, offer for sale and sell Licensed Compounds and Licensed
Products in the Field. It is understood that the foregoing license to Sunesis
Core Technology shall not include the right to practice Sunesis Core Technology
to discover novel compositions.

5.1.3 License for Reverted Licensed Products. Subject to the terms and
conditions of this Agreement (including Sections 5.1.1 and 5.1.2 above), with
respect to each Reverted Licensed Product Millennium hereby grants to Sunesis a
worldwide, exclusive license under Millennium’s interest in the Biogen Idec
Collaboration Technology, Joint Sunesis-Biogen Collaboration Technology,
Development Technology and other Patent Rights and Know How [ * ] the relevant
Licensed Product becomes a Reverted Licensed Product (“Other Millennium
Technology”), with the right to grant and authorize sublicenses as provided in
Section 5.2, to develop, make, have made, use, import, offer for sale, sell and
otherwise exploit such Reverted Licensed Product. It is understood and
acknowledged that the licenses granted with respect to Biogen Idec Collaboration
Technology, Development Technology and Other Millennium Technology in this
Section 5.1.3 extend solely to that technology that is being used on that
Reverted Licensed Product as of the date of such reversion to Sunesis, and
solely to the extent necessary for Sunesis to continue development and
commercialization of such Reverted Licensed Product in the form in which such
Reverted Licensed Product existed as of the date of such reversion to Sunesis.

 

-22-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

5.2. Grant of Sublicenses. Within a reasonable period of time following grant of
any sublicense, to the extent sublicensing is permitted under Section 5.1, the
sublicensing Party shall provide the other Party with a summary of such
sublicense, including the identity of the Sublicensee (including any Affiliate)
and the rights granted with respect thereto for each product and territory,
sufficient to allow such other Party to verify any amounts then or subsequently
due under Articles 6 and 7 below; provided that such summary may redact
confidential information that the sublicensing Party is reasonably prohibited
from disclosing under the sublicense agreement. Any sublicense granted under
this Section 5.2 shall be consistent with all of the terms and conditions of
this Agreement, and subordinate thereto, and the sublicensing Party shall remain
responsible to the other Party for the compliance of each such Sublicensee with
the obligations due under this Agreement.

5.3. Sunesis Covenant [ * ] Notwithstanding the foregoing, Sunesis shall not be
prohibited from collaborating with a Third Party on the development and
commercialization of chemical compounds in-licensed from or controlled by such
Third Party [ * ]; provided that Sunesis has not exercised the Co-Funding Option
with respect to a Licensed Product [ * ] and such compounds are in Phase II
clinical trials or later stage of development or commercialization at the time
of initiation of such collaboration (a “Phase II Drug Collaboration”). Sunesis
shall notify Millennium in writing upon entering into a Phase II Drug
Collaboration. Nothing in this Section 5.3 is intended as the grant of a license
by Millennium to Sunesis.

5.4. Assay License. Millennium hereby grants to Sunesis a fully-paid,
royalty-free worldwide, non-exclusive, perpetual, irrevocable license under
Millennium’s rights in the assays set forth on Exhibit 1.44 for use by Sunesis
solely to comply with Sunesis’s obligations under this Agreement.

5.5. No Other Rights; No Implied Licenses. Only the licenses granted or retained
pursuant to the express terms of this Agreement shall be of any legal force or
effect. No other license rights shall be created by implication, estoppel or
otherwise.

ARTICLE 6

PAYMENTS

6.1. Research Milestones. Millennium shall pay to Sunesis the following amounts
within thirty (30) days following the first achievement of the following
research milestones:

 

Research Milestones

   Payment Amount   1. Identification of the second Development Candidate
directed against the Raf Target (it being acknowledged and agreed that [ * ] is
the first such Licensed Compound for the Raf Target):      $[ * ]    2.
Identification of the second Development Candidate directed against the [ * ]
Target (it being acknowledged and agreed   

 

-23-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

Research Milestones

   Payment Amount that, as of the Effective Date, no GLP toxicity study or GMP
manufacturing has been initiated for the first such Licensed Compound):   
$[ * ]

6.2. Development Milestones.

6.2.1 Development Milestone Payments.

(a) Millennium shall pay Sunesis [ * ] Dollars ($[ * ]) within thirty (30) days
following the initiation of the first Phase I trial for a Licensed Product
directed against the [ * ] Target.

(b) With respect to each Licensed Product, Millennium shall pay to Sunesis on a
Licensed Product-by-Licensed Product basis the following amounts within
thirty (30) days following the first achievement by Millennium, its Affiliates
or Sublicensees, as the case may be, of each of the following milestones with
respect to such Licensed Product:

 

     Payment Amount

Development Milestones

   [ * ]

[ * ]

Such milestone payments shall be non-refundable and non-creditable against other
amounts due Sunesis hereunder.

6.2.2 Certain Additional Terms.

(a) Licensed Product-by-Licensed Product Milestones. It is understood that,
subject to Section 6.2.2(b), the payments under this Section 6.2 shall be due
only once with respect to each Licensed Product.

(b) Multiple Indications. With respect to a particular Licensed Product, [ * ]

(c) Discontinued Licensed Products. If Millennium ceases all clinical
development of a particular Licensed Product, after having made one or more of
the payments due under Section 6.2.1 above on the achievement of a particular
milestone by such Licensed Product, there shall be no payment due upon the
accomplishment of that same milestone with respect to the next Licensed Product
that is specifically directed at the same Designated Target to achieve such
milestone.

 

-24-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

(d) Accrued Milestones. If a development milestone for a Licensed Product under
Section 6.2.1 above is achieved with respect to such Licensed Product before a
prior development milestone under Section 6.2.1 for such Licensed Product, then
the earlier milestone payments shall then also be due with respect to such
Licensed Product.

6.2.3 Reports; Payments. Within ten (10) business days of the occurrence of any
event which would trigger a milestone payment according to Section 6.2,
Millennium shall inform Sunesis of such occurrence. The corresponding payment
shall be due thirty (30) days after the occurrence of such event.

6.3. Royalties on Annual Net Sales of Licensed Products.

6.3.1 Licensed Products Generally. Subject to Sections 6.3.2 and 6.3.3,
Millennium shall pay to Sunesis a royalty on Net Sales by Millennium, its
Affiliates and their Sublicensees of Licensed Products (other than Net Sales of
Co-Funded Products in the Co-Funded Territory) on a Licensed Product-by-Licensed
Product basis, equal to the percentage of such Net Sales set forth below:

 

Annual Net Sales    Royalty on Net Sales

Portion of Annual Net Sales of such Licensed Product up to $[ * ]:

   [ * ]%

Portion of Annual Net Sales of such Licensed Product between $[ * ] and $[ * ]:

   [ * ]%

Portion of Annual Net Sales of such Licensed Product between $[ * ] and $[ * ]:

   [ * ]%

Portion of Annual Net Sales of such Licensed Product over $[ * ]:

   [ * ]%

For purposes of the foregoing and Section 6.3.2 below, “Annual Net Sales” shall
mean, for a particular Licensed Product, the worldwide Net Sales of such
Licensed Product for the particular calendar year. In the event that in a
calendar quarter portions of the worldwide Net Sales of a particular Licensed
Product are subject to royalty obligations under both Sections 6.3.1 and 6.3.2,
the applicable royalty rate under Section 6.3.2 shall be applied to worldwide
Net Sales based on the proportion of worldwide Net Sales generated in the
Co-Funded Territory.

6.3.2 Compensation for Co-Funded Products.

(a) Subject to Sections 6.3.2(b), 6.3.2(c) and 6.3.3, in consideration for the
co-funding by Sunesis, Millennium shall pay to Sunesis an amount [ * ]

(b) [ * ]

[ * ]

6.3.3 Third Party Patents.

 

-25-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

(a) If: (i) a [ * ] of a Third Party should be in force in any country during
the Term of this Agreement covering the practice of the Sunesis Licensed
Technology or Sunesis Core Technology as licensed to Millennium under
Section 5.1 with respect to the manufacture, use or sale of any Licensed
Product, (ii) it should prove in Millennium’s reasonable judgment, after
consultation with Sunesis, [ * ] for Millennium to commercialize such Licensed
Product without obtaining a royalty bearing license from such Third Party [ * ]
(with such agreement not to be unreasonably withheld or delayed), and (iii) the
royalty paid to such Third Party is directed to the practice of rights granted
to Millennium under Section 5.1 with respect to such Licensed Product, then
Millennium shall be entitled to a credit against the royalty payments due under
the other provisions of this Section 6.3 with respect to the same Licensed
Product in such country of an amount equal to [ * ] of the royalty paid to such
Third Party for such Licensed Product in such country, arising from the practice
of such Sunesis Licensed Technology or Sunesis Core Technology with respect to
the manufacture, use or sale of the Licensed Product in said country, with such
credit not to exceed [ * ] of the royalty otherwise due under this Agreement for
such Licensed Product in such country.

(b) If: (i) a [ * ] of a Third Party should be in force in any country during
the Term of this Agreement covering the practice of the Biogen Idec
Collaboration Technology, Joint Sunesis-Biogen Collaboration Technology,
Development Technology or Other Millennium Technology licensed to Sunesis under
Section 5.1.3, in each case with respect to the manufacture, use or sale of any
Reverted Licensed Product, (ii) it should prove in Sunesis’s reasonable
judgment, after consultation with Millennium, [ * ] for Sunesis to commercialize
such Reverted Licensed Product without obtaining a royalty bearing license from
such Third Party [ * ] (with such agreement not to be unreasonably withheld or
delayed), and (iii) the royalty paid to such Third Party is directed to the
practice of rights granted to Sunesis under Section 5.1.3 with respect to such
Reverted Licensed Product, then Sunesis shall be entitled to a credit against
the royalty payments due under Section 6.4 with respect to the same Reverted
Licensed Product in such country of an amount equal to [ * ] of the royalty paid
to such Third Party for such Reverted Licensed Product in such country, arising
from the practice of the intellectual property described above with respect to
the manufacture, use or sale of the Reverted Licensed Product in said country,
with such credit not to exceed [ * ] of the royalty otherwise due under this
Agreement for such Reverted Licensed Product in such country.

6.4. Royalties on Net Sales of Reverted Licensed Products. Sunesis shall pay
Millennium at a royalty rate equal to the royalty rate provided under
Section 6.3.1 with respect to Net Sales of Reverted Licensed Products by
Sunesis, its Affiliates and their Sublicensees; provided, however, that such
royalty rate shall be [ * ] by [ * ] with respect to sales in the U.S. or Japan
during any portion of the applicable period under clause (ii) in Section 6.5.1
in which [ * ] the Biogen Idec Collaboration Patents, Joint Sunesis-Biogen
Collaboration Patents, Development Technology or Other Millennium Technology
Covers the sale or use of such Reverted Licensed Product in such country.

6.5. Royalty Term.

 

-26-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

6.5.1 The royalties due pursuant to Section 6.3 and Section 6.4 above shall be
payable on a country-by-country and Product-by-Product basis commencing on the
first commercial sale in a country and continuing until the later of: [ * ]

6.5.2 Millennium acknowledges that it will continue to benefit from its license
under, and the transfer to Millennium of certain elements of, the Sunesis
Collaboration Technology and Sunesis Core Technology, the co-funding payments
pursuant to this Agreement and Millennium’s own development of Know-How derived
from the practice of such Sunesis licenses and Millennium’s use of such Sunesis
Collaboration Technology and Sunesis Core Technology, even after the expiration
of all Patent Rights that claim a Licensed Product in a particular country of
the Territory. In addition, Millennium and Sunesis acknowledge the application
of a uniform royalty structure and compensation to Sunesis for its co-funding
payments in the form of an additional royalty payment amount throughout the
period under clause (ii) in Section 6.5.1. The Parties acknowledge that such
structure is more convenient to the Parties, facilitates the payment of
compensation between the Parties for co-funding commitments and access to
Know-How and reduces accounting burdens on the Parties. Accordingly, the Parties
have agreed to apply the royalty structure as provided in this Article 6.

ARTICLE 7

PAYMENTS, BOOKS AND RECORDS

7.1. Royalty Reports and Payments. After the first sale of a Product on which
royalties are payable by a Party hereunder, such Party shall make quarterly
written reports to the other Party within sixty (60) days after the end of each
calendar quarter, stating in each such report, separately the number,
description, and aggregate Net Sales, by territory, of each such Product sold
during the calendar quarter upon which a royalty is payable under Section 6.3 or
Section 6.4 above, as applicable. Concurrently with the making of such reports,
such Party shall pay to the other Party royalties due at the rates specified in
Section 6.3 or Section 6.4 above, as applicable.

7.2. Payment Method. All payments due under this Agreement shall be made by bank
wire transfer in immediately available funds to a bank account designated by the
Party owed such payment. All payments hereunder shall be made in U.S. dollars.
Any payments that are not paid on the date such payments are due under this
Agreement shall bear interest to the extent permitted by applicable law at a
rate equal to the 3-month LIBOR rate at the close of business on the date such
payment is due, plus an additional two percent (2%), calculated on the number of
days such payment is delinquent.

7.3. Place of Royalty Payment; Currency Conversion. The functional currency for
accounting will be U.S. dollars. Except as the Parties otherwise mutually agree,
for billing and reporting, Development Costs and Net Sales will be translated,
if necessary, into U.S. dollars using the currency exchange rates quoted by
Bloomberg Professional, a service of Bloomberg L.P., or in the event Bloomberg
Professional is not available, then the Eastern U.S. edition of The Wall Street
Journal on the last business day of the applicable calendar quarter.

 

-27-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

7.4. Records; Inspection. Each Party shall keep, and shall ensure that its
Affiliates keep, complete, true and accurate books of account and records for
the purpose of determining the amounts payable under this Agreement. Such books
and records shall be kept at the principal place of business of such Party, for
at least three (3) years following the end of the calendar quarter to which they
pertain. Such records will be open for inspection by a public accounting firm to
whom the audited Party has no reasonable objection and subject to such
accounting firm entering into a satisfactory confidentiality agreement, solely
for the purpose of determining the payments to the other Party hereunder. Such
inspections may be made no more than twice each calendar year, at reasonable
times and on reasonable notice. Inspections conducted under this Section 7.4
shall be at the expense of the auditing Party, unless a variation or error
producing an increase exceeding [ * ] percent ([ * ]%) of the amount stated for
the period covered by the inspection is established in the course of any such
inspection, whereupon all reasonable costs relating to the inspection for such
period and any unpaid or overpaid amounts that are discovered will be promptly
paid or refunded by the appropriate Party, in each case together with interest
noted in Section 7.2 thereon from the date such payments were due (if underpaid)
or paid (if overpaid).

7.5. Withholding Taxes. Each Party shall pay any and all taxes levied on account
of amounts payable to it under this Agreement. If laws or regulations require
that taxes be withheld, the paying Party will (i) deduct those taxes from the
remittable payment, (ii) timely pay the taxes to the proper authority, and
(iii) send proof of payment to the other Party within sixty (60) days following
that payment.

ARTICLE 8

DILIGENCE

8.1. Diligence; Reports. Millennium shall use Commercially Reasonable and
Diligent Efforts to develop and commercialize Co-Funded Products within the
Field. Millennium agrees to keep Sunesis fully informed regarding the
Development and commercialization activities with respect to each Co-Funded
Product by providing reports to Sunesis at least quarterly regarding ongoing
activities being undertaken with respect to Co-Funded Products. In addition,
Millennium shall provide Diligence Summaries to Sunesis with respect to each [ *
]. This Section 8.1 shall not limit other provisions of this Agreement that
address the provision of information regarding Licensed Products.

8.2. Reversion of a Co-Funded Product. If Millennium fails to use Commercially
Reasonable and Diligent Efforts to develop and commercialize a Co-Funded
Product, and Millennium shall continue to fail to use Commercially Reasonable
and Diligent Efforts to develop and commercialize such Co-Funded Product for [ *
] after written notice thereof from Sunesis, or in the event that Sunesis
terminates this Agreement pursuant to Section 13.2 for Millennium’s breach,
pursuant to Section 13.3 for Millennium’s bankruptcy or in the event that
Millennium terminates this Agreement pursuant to Section 13.4 for convenience
with respect to a Co-Funded Product, Sunesis shall have the right to assume the
development and commercialization of such Co-Funded Product, subject to the
terms and conditions of this Section 8.2, upon written notice to Millennium.
Upon the effective date of such notice from

 

-28-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

Sunesis, such Co-Funded Product shall be designated a “Reverted Licensed
Product”, the terms set forth in Section 1 of Exhibit 8.2 attached hereto shall
thereafter apply, and Sunesis shall pay royalties to Millennium as provided
under Section 6.4 on Net Sales of such Reverted Licensed Product by Sunesis, its
Affiliates or Sublicensees.

8.3. Diligence for a Reverted Licensed Product. Sunesis shall use Commercially
Reasonable and Diligent Efforts to develop and commercialize each Reverted
Licensed Product. Sunesis agrees to keep Millennium fully informed regarding the
development and commercialization activities with respect to each Reverted
Licensed Product, including by providing Millennium with reports at least
quarterly regarding ongoing activities being undertaken with respect to Reverted
Licensed Products. In addition, Sunesis shall provide Millennium with a
Diligence Summary with respect to each Reverted Licensed Product on a
semi-annual basis during the Term of this Agreement.

8.4. Termination of a Reverted Licensed Product. If Sunesis fails to use
Commercially Reasonable and Diligent Efforts to develop and commercialize a
Reverted Licensed Product, and Sunesis shall continue to fail to use
Commercially Reasonable and Diligent Efforts to develop and commercialize such
Reverted Licensed Product for sixty (60) days after written notice thereof from
Millennium, then such Reverted Licensed Product shall cease to be a Reverted
Licensed Product, and the license granted to Sunesis under Section 5.1.3 shall
terminate with respect to such Reverted Licensed Product. Thereafter, such
Reverted Licensed Product shall be a Licensed Product and subject to
Millennium’s licenses under Section 5.1 and obligations to pay royalties and
milestones to Sunesis pursuant to Article 6. In addition, the terms set forth in
Section 2 of Exhibit 8.2 shall apply to such Reverted Licensed Product.

8.5. Disputes. In the event that there is a good faith dispute as to whether the
activities described in a Diligence Summary constitute Commercially Reasonable
and Diligent Efforts to develop and commercialize the applicable Co-Funded
Product or Reverted Licensed Product, then either Party may refer the dispute
for a prompt determination by the JSC. In the event that the JSC is unable to
reach consensus on such determination, then the matter shall be referred to the
Parties’ respective Chief Medical Officers (or the equivalent if there is no
such Chief Medical Officer of a Party). Upon such request, the Chief Medical
Officers shall make themselves reasonably available to meet, and shall meet
either by telephone or if, specifically requested, in person, to attempt to
resolve such matter, and shall thereafter continue to use good faith efforts to
attempt to resolve such matter unless it becomes clear that the matter cannot be
resolved by mutual agreement. Thereafter either Party may pursue such legal
process as is otherwise available under applicable law.

 

-29-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

ARTICLE 9

INTELLECTUAL PROPERTY

9.1. Ownership; Disclosure.

9.1.1 Collaboration Technology.

(a) Raf Technology. All right, title, and interest in and to the Sunesis
Collaboration Patents and Joint Sunesis-Biogen Collaboration Patents, the
subject of which are inventions that were developed in the course of activities
directed to the Raf Target or to the discovery, research, or development of
Licensed Compounds which are Target Selective to the Raf Target or Licensed
Products incorporating such Licensed Compounds (the “Raf Patents”) were jointly
and equally owned by Biogen Idec and Sunesis under the Original Agreement.
Pursuant to the Millennium-Biogen Agreement, Biogen Idec has, with the consent
of Sunesis as provided in the Three Party Agreement, assigned all of its right,
title and interest in and to the Raf Patents to Millennium; and from and after
the Effective Date the Raf Patents shall be jointly owned by Millennium and
Sunesis.

(b) Sunesis Collaboration Technology. Subject to Section 9.1.1(a), all right,
title, and interest in and to the Sunesis Collaboration Technology shall be
owned by Sunesis, subject to the licenses granted to Millennium under Article 5.

(c) Joint Sunesis-Biogen Collaboration Technology. Pursuant to the
Millennium-Biogen Agreement, Biogen Idec has, with the consent of Sunesis as
provided in the Three Party Agreement, assigned to Millennium all of its right,
title and interest in and to the Joint Sunesis-Biogen Collaboration Patents and
Joint Sunesis-Biogen Collaboration Know-How that are included in the Assigned IP
(as defined in the Millennium-Biogen Agreement) and that, in each case, are [ *
] a Licensed Compound (the “Licensed Compound Joint Technology”) and has granted
a license to Millennium under Biogen Idec’s right, title and interest in and to
all other Joint Sunesis-Biogen Patents and Joint Sunesis-Biogen Know-How (the
“Other Joint Technology”). All right, title and interest in and to the Licensed
Compound Joint Technology shall be jointly owned by the Parties. All right,
title and interest in and to the Other Joint Technology shall be jointly owned
by Sunesis and Biogen Idec (subject to the licenses granted to Millennium).
Except as expressly provided in this Agreement, neither Party shall have any
obligation to account to the other for profits, or to obtain any approval of the
other Party to license, exploit or enforce the Licensed Compound Joint
Technology, by reason of joint ownership thereof, and each Party hereby waives
any right it may have under the laws of any jurisdiction to require any
accounting or consent related thereto. It is understood and agreed that all
Joint Sunesis-Biogen Collaboration Technology that is jointly owned pursuant to
Section 9.1.1(a) and this Section 9.1.1(c) shall be subject to the licenses
granted under Article 5.

(d) Excluded Compounds. For the avoidance of doubt, to the extent a Joint
Sunesis-Biogen Collaboration Patent discloses any use of an Excluded Compound
(as defined in the Original Agreement), the composition of matter of which is
separately owned by one Party, the other Party shall not have, merely as a
result of its joint ownership of such Joint

 

-30-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

Sunesis-Biogen Collaboration Patent, any right, title or interest in or to such
Excluded Compound.

9.1.2 Development Technology. All right, title and interest in and to the
Development Technology shall, as between the Parties, be owned solely by
Millennium. Sunesis hereby assigns to Millennium all of Sunesis’s and its
Affiliates’ rights in and to the Development Technology (including all patent
and other intellectual property rights therein), subject to the licenses granted
to Sunesis under Article 5.

9.2. Patent Prosecution. Subject to the rights of Biogen Idec under the
Millennium-Biogen Agreement:

9.2.1 Sunesis Core Technology. Sunesis shall have the right to control the
preparation, filing, prosecution and maintenance of patent applications and
patents directed to Sunesis Core Technology using patent counsel of Sunesis’s
choice, provided that such decisions made by Sunesis in the preparation, filing,
prosecution, and maintenance of such patents and patent applications shall be
reasonable and Sunesis shall employ reasonable efforts not to substantially
negatively impact Millennium’s rights hereunder.

9.2.2 Collaboration Patents. Millennium shall have the first right, using
in-house or outside legal counsel selected by Millennium, subject to approval,
not to be unreasonably withheld, by Sunesis, to prepare, file, prosecute,
maintain, and obtain extensions of Collaboration Patents throughout the world.
Millennium shall: (a) ensure that Sunesis receives copies of all correspondence
between Millennium or outside legal counsel or any governmental offices relating
to such preparation, filing, prosecution, maintenance, and obtaining of
extensions, of such Collaboration Patents, (b) timely consult with Sunesis
regarding all substantive matters associated with such activities, (c) use
reasonable efforts to periodically advise Sunesis on such activities and to
respond to any reasonable inquiries Sunesis may from time to time raise in
respect of such activities, and (d) not substantially negatively impact
Sunesis’s rights under such Collaboration Patents. As used herein, “prosecution”
shall include interferences, re-examinations, reissues, oppositions and the
like.

9.2.3 Prosecution Costs. During the Term of this Agreement, all costs associated
with filing, prosecuting, issuing, maintaining, and extending (i) patent
applications and patents within the Sunesis Core Technology shall be borne by
Sunesis; and (ii) the Collaboration Patents shall be borne by Millennium.

9.2.4 Cooperation. Each Party will cooperate fully with the other Party and
provide all information and data, and sign any documents, reasonably necessary
and requested by the other Party for the purpose of preparing, filing and
prosecuting patent applications pursuant to this Section 9.2.

9.2.5 Abandonment. Millennium may elect to decline to file or, having filed,
decline to further prosecute and maintain any Collaboration Patent, in which
event Millennium shall provide Sunesis with written notice thereof prior to the
expiration of any deadline, without considering any possible extensions thereof,
relating to such activities, but in any event at least

 

-31-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

thirty five (35) business days prior notice. In such circumstances Sunesis shall
have the right to decide, with reason and with written notice at least thirty
(30) business days prior to the deadline, that Millennium should continue to
file or prosecute such Collaboration Patent. Millennium shall then have the
option to decide, with at least twenty (20) business days notice to Sunesis to:
(i) continue to file or prosecute such Collaboration Patent at its cost and
expense, or (ii) allow Sunesis to file or prosecute such Collaboration Patent at
its own cost and expense using counsel of its own choice. In the event that
Millennium elects option (ii), then Millennium shall cooperate with Sunesis to
promptly transfer relevant prosecution materials to Sunesis. It is understood
and agreed that transfer of prosecution of particular Collaboration Patents
pursuant to subsection (ii) above shall not affect the ownership or licenses
otherwise provided in this Agreement.

9.3. Enforcement. Subject to the rights of Biogen Idec under the
Millennium-Biogen Agreement:

9.3.1 Notice. In the event a Party becomes aware of any actual or potential
infringement or misappropriation of the Sunesis Licensed Technology (a “Subject
Infringement”), such Party shall notify the other Party.

9.3.2 Millennium. Subject to the terms of this Section 9.3.2, Millennium shall
have the sole right, but not the obligation, to take legal action to enforce and
defend the Sunesis Licensed Technology against Subject Infringements by Third
Parties at its sole cost and expense, to the extent such Subject Infringement is
within the field of use of Millennium’s exclusive license under Section 5.1.1
above. If, within [ * ] following a request by Sunesis to do so, Millennium
fails to take such action to enforce the Sunesis Licensed Patents with respect
to a Subject Infringement, Sunesis or its designee shall, in its sole
discretion, have the right, at its sole expense, to take such action. In
addition, Millennium shall have the sole right, but not the obligation, to take
legal action to enforce and defend any actual or potential infringement or
misappropriation of the Biogen Idec Collaboration Technology.

9.3.3 Sunesis. To the extent a Subject Infringement is not covered by
Section 9.3.2 above, Sunesis (or its designee) shall have the initial right, but
not the obligation, to take reasonable legal action to enforce and defend the
Sunesis Licensed Technology against such Subject Infringements by Third Parties
at its sole cost and expense. If, within [ * ] following a request by Millennium
to do so, Sunesis fails to take such action to enforce the Sunesis Licensed
Patents with respect to such Subject Infringement, and the Subject Infringement
is in a field not then licensed exclusively to Sunesis hereunder, Millennium or
its designee shall, in its sole discretion, have the right, at its sole expense,
to take such action.

9.3.4 Cooperation; Costs and Recoveries. If a Party (the “Controlling Party”)
brings an action with respect to a Subject Infringement in accordance with this
Section 9.3 (an “Infringement Action”), then the other Party (the “Cooperating
Party”) shall cooperate as reasonably requested, at such Controlling Party’s
expense, in the pursuit of such Infringement Action, including if necessary by
joining as a nominal Party to the Infringement Action. In any case, the
Cooperating Party shall have the right, even if not required to be joined, to
participate in

 

-32-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

such Infringement Action with its own counsel at its own expense. The costs and
expenses of the Infringement Action shall be the responsibility of the
Controlling Party, and any damages or other monetary rewards or settlement
payments actually received and retained by the Controlling Party shall first be
applied to reimburse the Controlling Party’s out-of-pocket expenses directly
attributed to the Infringement Action, then the other Party’s out-of-pocket
expenses directly attributed to the Infringement Action, and the remainder shall
be shared as follows: [ * ]

ARTICLE 10

CONFIDENTIALITY

10.1. Confidentiality. During the Term of this Agreement and for a period of [ *
] years following the expiration or earlier termination hereof, each Party shall
maintain in confidence the Confidential Information of the other Party, shall
not use or grant the use of the Confidential Information of the other Party
except as expressly permitted hereby, and shall not disclose the Confidential
Information of the other Party (in each case, irrespective of whether such
Confidential Information is also the Confidential Information of the receiving
Party), except (i) on a need-to-know basis to such Party’s directors, officers
and employees, (ii) to such Party’s consultants performing work contemplated by
the Agreement, and to any bona fide subcontractor performing work for such Party
hereunder, or (iii) to the extent such disclosure is reasonably necessary in
connection with such Party’s activities under rights and licenses expressly
authorized by this Agreement (including the permitted sublicensees). To the
extent that disclosure to any person is authorized by this Agreement, prior to
disclosure, a Party shall obtain written agreement of such person to hold in
confidence and not disclose, use or grant the use of the Confidential
Information of the other Party except as expressly permitted under this
Agreement. Each Party shall notify the other Party promptly upon discovery of
any unauthorized use or disclosure of the other Party’s Confidential
Information.

10.2. Permitted Use and Disclosures. The confidentiality obligations under this
Article 10 shall not apply to the extent that a Party is required to disclose
information by applicable law, regulation or order of a governmental agency or a
court of competent jurisdiction; provided, however, that such Party shall
provide written notice thereof to the other Party (to the extent not prohibited
by law or court order), and consult with the other Party with respect to such
disclosure to the extent reasonably protectable and provide the other party
reasonable opportunity to object to any such disclosure or to request
confidential treatment thereof. Notwithstanding the provisions of this Section,
either Party may, to the extent necessary, disclose Confidential Information of
the other Party, to any governmental or regulatory authority in connection with
the development of a product which it has the right to develop under this
Agreement.

10.3. Nondisclosure of Terms. Each of the Parties hereto agrees not to disclose
the financial terms of this Agreement to any Third Party without the prior
written consent of the other Party hereto, which consent shall not be
unreasonably withheld, except (a) to such Party’s attorneys, advisors,
investors, potential bona fide collaborators and Sublicensees, and others on a
need-to-know basis under circumstances that reasonably protect the
confidentiality thereof; (b) or to the extent required by law (and with
appropriate requests made for confidential treatment),

 

-33-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

including filings required to made by law with the Securities and Exchange
Commission or any national securities exchange; provided, however, that, with
respect to any filing required to made by law with the Securities and Exchange
Commission or any national securities exchange, the Party subject to such filing
requirement shall, at least ten (10) business days in advance of any such
filing, provide the other Party with a draft set of redactions to this Agreement
for which confidential treatment will be sought, reasonably incorporate the
other Party’s comments as to additional terms it would like to see redacted, and
seek confidential treatment for such additional terms (except only in the
limited circumstances where confidential treatment is in the opinion of outside
counsel unavailable); or (c) to Biogen Idec, to the extent required under the
Three Party Agreement or Millennium-Biogen Agreement. Notwithstanding the
foregoing, (i) Sunesis may issue the press release to be mutually agreed by the
Parties, and (ii) each Party may disclose the information contained in such
press release (and related Securities and Exchange Commission filing) without
the consent of the other Party.

10.4. Publication.

10.4.1 By Sunesis. Any manuscript by Sunesis on subject matter in connection
with the Research Program relating to the Designated Targets or Licensed
Compounds to be published or publicly disclosed shall be subject to the prior
review of Millennium at least [ * ] prior to submission. Further, to avoid loss
of patent rights as a result of premature public disclosure of patentable
information, Millennium shall notify Sunesis in writing within [ * ] after
receipt of any disclosure whether Millennium desires to file a patent
application on any invention disclosed in such scientific results. In the event
that Millennium desires to file such a patent application, Sunesis shall
withhold publication or disclosure of such scientific results until the earlier
of (i) a patent application is filed thereon, (ii) the Parties determine after
consultation that no patentable invention exists, or (iii) [ * ] after receipt
by Sunesis of Millennium’s written notice of Millennium’s desire to file such
patent application. Further, if such scientific results contain the information
of Millennium that is subject to use and nondisclosure restrictions under this
Article 10, Sunesis agrees to remove such information from the proposed
publication or disclosure. For clarity, nothing in this Section 10.4 shall be
deemed to limit the publication or disclosure right of Sunesis with respect to a
Reverted Licensed Product.

10.4.2 By Millennium. Millennium shall have the right, but not the obligation,
to publish or publicly disclose, in its sole discretion, any manuscript
containing scientific or clinical results generated during the Term relating to
the Designated Targets, Licensed Compounds or Licensed Products, and shall
provide Sunesis with a courtesy copy of such manuscript prior to its
publication.

10.4.3 Patent Applications. Following the filing of any patent application
within the Collaboration Technology, in the period prior to the publication of
such a patent application, neither Party shall make any written public
disclosure regarding any invention claimed in such patent application without
the prior consent of the other Party.

 

-34-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

ARTICLE 11

REPRESENTATIONS AND WARRANTIES

11.1. Warranty. Each Party represents and warrants on its own behalf and on
behalf of its Affiliates that:

(i) Such Party is duly organized, validly existing and in good standing under
the laws of the jurisdiction in which it is organized.

(ii) It has the legal power and authority to enter into this Agreement and to
perform all of its obligations hereunder.

(iii) This Agreement is a legal and valid obligation binding upon it and
enforceable in accordance with its terms.

(iv) All necessary consents, approvals and authorizations of all governmental
authorities and other persons or entities required to be obtained by such Party
in connection with this Agreement have been obtained.

(v) The execution and delivery of this Agreement and the performance of such
Party’s obligations hereunder (a) do not conflict with or violate any
requirement of applicable laws, regulations or orders of governmental bodies;
and (b) do not conflict with, or constitute a default under, any contractual
obligation of such Party. Neither Party will enter into any agreement with any
Third Party that conflicts with the terms of this Agreement.

(vi) Such Party requires, and shall require, that all of its employees and
consultants involved in the Development, manufacture or commercialization of
Licensed Compounds, Licensed Products, Reverted Compounds or Reverted Licensed
Products have entered into written agreements obligating such person to assign
any rights s/he may have in any inventions made during such work to such Party.

11.2. Additional Warranty of Sunesis. Sunesis represents and warrants as of the
Effective Date that:

(a) to the best of its knowledge, the practice of the Sunesis Core Technology
with respect to the Licensed Compounds is not generally dominated by Patent
Rights of a Third Party;

(b) Sunesis has not received any notice of infringement from any Third Party
relating to the Sunesis Core Technology or Sunesis Licensed Technology;

(c) Sunesis has not received any notice challenging the validity of the Sunesis
Licensed Technology or Sunesis Core Technology; and

 

-35-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

(d) to the best of its knowledge, the Sunesis Licensed Technology and Sunesis
Core Technology with respect to Licensed Compounds is legally possessed by
Sunesis and has not been misappropriated from any Third Party.

11.3. Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT,
NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER
EXPRESS OR IMPLIED, WITH RESPECT TO THE COLLABORATION TECHNOLOGY, SUNESIS CORE
TECHNOLOGY, DEVELOPMENT TECHNOLOGY, OTHER MILLENNIUM TECHNOLOGY, LICENSED
COMPOUNDS, OTHER COMPOUNDS, LICENSED PRODUCTS, DESIGNATED TARGETS OR
CONFIDENTIAL INFORMATION, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE, VALIDITY OF ANY COLLABORATION TECHNOLOGY, PATENTED OR
UNPATENTED, OR NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD
PARTIES.

ARTICLE 12

INDEMNIFICATION

12.1. Millennium. Millennium shall indemnify, defend and hold harmless Sunesis
and its Affiliates and their respective directors, officers, employees, agents
and their respective successors, heirs and assigns from and against any losses,
costs, claims, damages, liabilities or expense (including reasonable attorneys’
and professional fees and other expenses of litigation) (collectively,
“Liabilities”) resulting from any claims, demands, actions or other proceedings
by any Third Party to the extent resulting from: (i) the manufacture, use, sale,
handling or storage of Licensed Products by Millennium or its Affiliates or
Sublicensees or other designees (except with respect to claims of infringement
or violation of intellectual property rights, which shall be governed solely by
clause (iv)); (ii) the breach by Millennium of the representations and
warranties made in this Agreement; (iii) [ * ] Millennium or any of its agents
or employees or failure of Millennium or any of its agents or employees to
comply with applicable laws and regulations; or (iv) a claim that the use,
manufacture, sale or importation of a Licensed Product infringes or violates the
intellectual property rights of a Third Party (other than if such infringement
or violation results solely from the practice of any Sunesis Licensed Technology
(excluding any Joint Sunesis-Biogen Idec Collaboration Patents and Joint
Sunesis-Biogen Idec Collaboration Know-How) and Sunesis Core Technology in
accordance with this Agreement); except, in each of cases (i)–(iv), to the
extent such Liabilities result from a material breach of this Agreement by
Sunesis, [ * ] Sunesis or any of its agents or employees (including sales
representatives involved in co-promoting any Co-Promoted Licensed Product) or
failure of Sunesis or any of its employees or agents to comply with applicable
laws or regulations.

12.2. Sunesis. Sunesis agrees to indemnify, defend and hold harmless Millennium
and its Affiliates and their respective directors, officers, employees, agents
and their respective heirs and assigns from and against any Liabilities
resulting from any claims, demands, actions or other proceedings by any Third
Party to the extent resulting from: (i) the manufacture, use, sale, handling or
storage of Co-Promoted Licensed Products or Reverted Licensed Products by

 

-36-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

Sunesis or its Affiliates or Sublicensees or other designees, (ii) the breach by
Sunesis of its representations and warranties made in this Agreement or the
Original Agreement, or (iii) [ * ] Sunesis or any of its agents or employees or
failure of Sunesis or any of its agents or employees to comply with applicable
laws and regulations; except, in each case, to the extent such Liabilities
result from a breach of this Agreement by Millennium, [ * ] Millennium or any of
its agents or employees (including sales representatives involved in
co-promoting any Co-Promoted Licensed Product) or failure of Millennium or any
of its employees or agents to comply with applicable laws or regulations.

12.3. Procedure. If a Party (the “Indemnitee”) intends to claim indemnification
under this Article 12, it shall promptly notify the other Party (the
“Indemnitor”) in writing of any claim, demand, action or other proceeding for
which the Indemnitee intends to claim such indemnification, and the Indemnitor
shall have the right to participate in, and, to the extent the Indemnitor so
desires, to assume the defense thereof with counsel mutually satisfactory to the
Parties; provided, however, that an Indemnitee shall have the right to retain
its own counsel, with the fees and expenses to be paid by the Indemnitor, if
representation of such Indemnitee by the counsel retained by the Indemnitor
would be inappropriate due to actual or potential differing interests between
the Indemnitee and any other Party represented by such counsel in such
proceeding. The obligations of this Article 12 shall not apply to amounts paid
in settlement of any claim, demand, action or other proceeding if such
settlement is effected without the consent of the Indemnitor, which consent
shall not be withheld or delayed unreasonably. The failure to deliver written
notice to the Indemnitor within a reasonable time after the commencement of any
such action, if prejudicial to its ability to defend such action, shall relieve
the Indemnitor of any obligation to the Indemnitee under this Article 12. The
Indemnitee, its employees and agents, shall reasonably cooperate with the
Indemnitor and its legal representatives in the investigation of any claim,
demand, action or other proceeding covered by this Article 12. The Indemnitor
shall not, without the Indemnitee’s consent, which consent shall not be withheld
or delayed unreasonably, consent to the entry of any judgment or accept any
settlement with respect to such claim, demand, action or proceeding which
imposes liability not covered by this indemnification or restrictions on the
Indemnitee.

ARTICLE 13

TERM AND TERMINATION

13.1. Term. The Term of this Agreement shall commence on the Effective Date, and
shall continue in full force and effect on a country-by-country and
Product-by-Product basis until expiration of both Parties’ royalty payment
obligations in such country with respect to such Products, in each case unless
earlier terminated as provided in this Article 13 (the “Term”).

13.2. Termination for Breach. Either Party to this Agreement may terminate this
Agreement in the event the other Party hereto shall have materially breached or
defaulted in the performance of any of its material obligations hereunder, and
such default shall have continued for [ * ] after written notice thereof was
provided to the breaching Party by the non-breaching Party. Any termination
shall become effective at the end of such [ * ] period unless the breaching
Party has cured any such breach or default prior to the expiration of the [ * ]
period.

 

-37-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

Notwithstanding the foregoing, failure by either Party to use Commercially
Reasonable and Diligent Efforts with respect to the development and
commercialization of a Product shall not be deemed a breach of this Agreement.
Sunesis hereby waives any breaches or defaults by Biogen Idec under the Original
Agreement and acknowledges and agrees that any future breaches or defaults by
Biogen Idec under the New Sunesis-Biogen Agreement shall have no bearing on this
Agreement.

13.3. Termination For Bankruptcy. Either Party hereto shall have the right to
terminate this Agreement forthwith by written notice to the other Party (i) if
the other Party is declared insolvent or bankrupt by a court of competent
jurisdiction, (ii) if a voluntary or involuntary petition in bankruptcy is filed
in any court of competent jurisdiction against the other Party and such petition
is not dismissed within ninety (90) days after filing, (iii) if the other Party
shall make or execute an assignment of substantially all of its assets for the
benefit of creditors, or (iv) substantially all of the assets of such other
Party are seized or attached and not released within ninety (90) days
thereafter. All rights and licenses granted under this Agreement by one Party to
the other Party are, and shall otherwise be deemed for purposes of
Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual
property” as defined under Section 101 (56) of the Bankruptcy Code. The Parties
agree that the licensing Party under this Agreement shall retain and may fully
exercise all of its rights and elections under the Bankruptcy Code in the event
of a bankruptcy by the other Party. The Parties further agree that in the event
of the commencement of a bankruptcy proceeding by or against one Party under the
Bankruptcy Code, the other Party shall be entitled to complete access to any
such intellectual property pertaining to the rights granted in the licenses
hereunder of the Party by or against whom a bankruptcy proceeding has been
commenced and all embodiments of such intellectual property.

13.4. Termination for Convenience by Millennium. Provided that Millennium is not
in breach of this Agreement, Millennium will have the right to terminate this
Agreement at any time, by providing [ * ] prior written notice.

13.5. Effect of Breach or Termination.

13.5.1 Accrued Rights and Obligations. Termination of this Agreement for any
reason shall not release either Party hereto from any liability which, at the
time of such termination, has already accrued to the other Party or which is
attributable to a period prior to such termination nor preclude either Party
from pursuing any rights and remedies it may have hereunder or at law or in
equity with respect to any breach of this Agreement.

13.5.2 Termination by Millennium for Breach or Bankruptcy of Sunesis. In the
event of termination of this Agreement by Millennium pursuant to Section 13.2
due to Sunesis’s breach or by Millennium pursuant to Section 13.3 for Sunesis’s
bankruptcy, in addition to those provisions surviving under Section 13.8, the
following shall apply:

(a) Sections 2.5.1 (Research Records); 2.5.2 (Inspections) (but only with
respect to Millennium’s rights and Sunesis’s obligations); 5.1.3 (License for
Reverted Licensed Products) (but only with respect to Reverted Licensed Products
in existence as of the effective date of such termination); 6.1 (Research
Milestones); 6.2 (Development Milestones); 6.3

 

-38-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

(Royalties on Annual Net Sales of Licensed Products) (except that any royalties
payable by Millennium thereunder, commencing upon such termination and
continuing thereafter, shall be reduced by [ * ]); 6.4 (Royalties on Net Sales
of Reverted Licensed Products); 6.5 (Royalty Term); Article 9 (Intellectual
Property) (other than Sections 9.2.2 and 9.2.3, which shall terminate); and
Exhibit 8.2 (Reverted Licensed Products) (but only with respect to Reverted
Licensed Products in existence as of the effective date of such termination)
shall survive.

(b) Subject to the rights of Biogen Idec under the Millennium-Biogen Agreement,
Millennium shall control prosecution of all Collaboration Patents (including
Sunesis Collaboration Patents, Biogen Idec Collaboration Patents and Joint
Sunesis-Biogen Collaboration Patents) at its own expense. Sunesis shall be given
the opportunity to review Millennium’s activities and reasonably consult with
Millennium with respect to Sunesis Collaboration Patents and Joint
Sunesis-Biogen Collaboration Patents, and Millennium shall in good faith
consider including in such patent applications such claims as Sunesis reasonably
requests. Millennium shall keep Sunesis reasonably informed as to the status of
such patent matters, including by providing Sunesis with (i) copies of any
documents relating to Sunesis Collaboration Patents and Joint Sunesis-Biogen
Collaboration Patents which Millennium receives from any patent office within
twenty (20) days of receipt thereof, including notice of all interferences,
reissues, reexaminations, oppositions or requests for patent term extensions,
and (ii) the opportunity to review and comment on any documents relating to
Sunesis Collaboration Patents and Joint Sunesis-Biogen Collaboration Patents
which will be filed in any patent office as soon practicable but in all cases at
least twenty (20) days prior to such filing. All costs associated with filing,
prosecuting, issuing and maintaining patent applications and patents within the
Sunesis Core Technology shall be borne by Sunesis. In conducting the prosecution
activities described in this Section 13.5.2(b), each Party shall employ
reasonable efforts not to substantially negatively impact the other Party’s
rights under the surviving provisions of this Agreement.

(c) Sunesis’s rights and obligations under Section 2.2.3 shall survive with
respect to Co-Funded Products for which Sunesis has exercised its Co-Funding
Option prior to such termination, and Millennium shall pay royalties on any such
Co-Funded Products in accordance with Section 6.3.2. Millennium shall no longer
be obligated to provide the detailed plans required of a Co-Development Plan and
Budget to Sunesis, but shall provide Sunesis with annual budgets of post Phase I
Development Costs for any such Co-Funded Products. Sunesis’s Co-Funding Option
with respect to future Licensed Products shall terminate, as will Article 3, as
well as Sunesis’s right to participate in the JDC under Section 4.3 and any
Licensed Product Teams under Section 2.3.

13.5.3 Termination by Sunesis for Breach or Bankruptcy of Millennium. In the
event of any termination by Sunesis pursuant to Section 13.2 due to Millennium’s
breach or pursuant to Section 13.3 for Millennium’s bankruptcy, in addition to
those provisions surviving under Section 13.8, the following provisions of this
Section 13.5.3 shall apply:

(a) Sections 2.5.1 (Research Records); 2.5.2 (Inspections) (but only with
respect to Sunesis’s rights and Millennium’s obligations); 5.1.3 (License for
Reverted Licensed

 

-39-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

Products); 6.1 (Research Milestones); 6.2 (Development Milestones); 6.3
(Royalties on Annual Net Sales of Licensed Products); 6.4 (Royalties on Net
Sales of Reverted Licensed Products (except that any royalties payable by
Sunesis thereunder, commencing upon such termination and continuing thereafter,
shall be reduced by [ * ]); 6.5 (Royalty Term); Article 8 (Diligence); Article 9
(Intellectual Property) (other than Sections 9.2.2 and 9.2.3, which shall
terminate); and Exhibit 8.2 (Reverted Licensed Products) shall survive, in
addition to those provisions surviving under Section 13.8.

(b) Subject to the rights of Biogen Idec under the Millennium-Biogen Agreement,
Millennium shall control prosecution of all the Biogen Idec Collaboration
Patents and Joint Sunesis-Biogen Collaboration Patents at its own expense.
Sunesis shall control prosecution of all Sunesis Collaboration Patents at its
own expense. Sunesis shall be given the opportunity to review Millennium’s
activities and reasonably consult with Millennium with respect to Joint
Sunesis-Biogen Collaboration Patents, and Millennium shall in good faith
consider including in such patent applications such claims as Sunesis reasonably
requests. Millennium shall keep Sunesis reasonably informed as to the status of
such patent matters, including by providing Sunesis with (i) copies of any
documents relating to Joint Sunesis-Biogen Collaboration Patents which
Millennium receives from any patent office within twenty (20) days of receipt
thereof, including notice of all interferences, reissues, reexaminations,
oppositions or requests for patent term extensions, and (ii) the opportunity to
review and comment on any documents relating to Joint Sunesis-Biogen
Collaboration Patents which will be filed in any patent office as soon
practicable but in all cases at least twenty (20) days prior to such filing. All
costs associated with filing, prosecuting, issuing and maintaining patent
applications and patents within the Sunesis Core Technology shall be borne by
Sunesis. In conducting the prosecution activities described in this
Section 13.5.3(b), each Party shall employ reasonable efforts not to
substantially negatively impact the other Party’s rights under the surviving
provisions of this Agreement.

(c) Millennium’s rights with respect to Co-Funded Products and the Co-Funded
Option shall be as follows:

(i) With respect to any Co-Funded Product for which Sunesis has exercised its
Co-Funding Option, and for which Millennium has not obtained Regulatory Approval
in any territory in the Co-Funded Territory for such Co-Funded Product, in each
case as of the effective date of such termination, such Co-Funded Product shall
become a Reverted Licensed Product in accordance with Section 8.2 and Exhibit
8.2 and Sunesis shall thereafter pay royalties to Millennium on Net Sales of
such Reverted Licensed Product in accordance with Section 6.4.

(ii) With respect to any Co-Funded Product for which Sunesis has exercised its
Co-Funding Option, and for which Millennium has obtained Regulatory Approval in
any territory in the Co-Funded Territory for such Co-Funded Product, in each
case as of the effective date of such termination, Sunesis’s rights and
obligations under Section 2.2.3 shall survive, and Millennium shall pay
royalties on any such Co-Funded Products in accordance with Section 6.3.2.
Millennium shall no longer be obligated to provide the detailed plans

 

-40-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

required of a Co-Development Plan and Budget to Sunesis, but shall provide
Sunesis with annual budgets of post Phase I Development Costs for any such
Co-Funded Products. Sunesis’s Co-Funding Option with respect to future Licensed
Products shall terminate, as will Article 3, as well as Sunesis’s right to
participate in the JDC under Section 4.3 and any Licensed Product Teams under
Section 2.3.

(iii) Sunesis’s Co-Funding Option under Section 2.2 with respect to future
Licensed Products shall continue (i.e., with respect to Licensed Products that
are not Co-Funded Products as of the effective date of such termination),
provided that Millennium shall no longer be obligated to provide for each
Licensed Product the detailed plans and clinical data required of an Initial
Development Plan and Phase II Notice pursuant to Section 2.2.1. Millennium
shall, however, provide Sunesis with annual budgets of post Phase I Development
Costs for such Co-Funded Product in accordance with the timetable for a Phase II
Notice set forth in Section 2.2.1, and shall provide reasonable cooperation to
Sunesis in evaluating such Co-Funded Product and the post Phase I Development
Costs related thereto, including consulting with Sunesis in good faith regarding
such annual budgets and the financial, scientific and regulatory assumptions
reflected therein.

13.6. Termination by Millennium for Convenience. In the event of termination of
this Agreement pursuant to Section 13.4, in addition to those provisions
surviving under Section 13.8, the following shall apply:

13.6.1 Sections 2.5.1 (Research Records); 2.5.2 (Inspections); Articles 2
(Product Development); 3 (Product Commercialization); 4 (Management); 5.1.3
(License for Reverted Licensed Products); 6.1 (Research Milestones); 6.2
(Development Milestones); 6.3 (Royalties on Annual Net Sales of Licensed
Products); 6.4 (Royalties on Net Sales of Reverted Licensed Products) (except
that any royalties payable by Sunesis thereunder, commencing upon such
termination and continuing thereafter, shall be reduced by [ * ]); Section 6.5
(Royalty Term); Article 8 (Diligence); Article 9 (Intellectual Property) (other
than Sections 9.2.2 and 9.2.3, which shall terminate); and Exhibit 8.2 (Reverted
Licensed Products) shall survive, in addition to those provisions surviving
under Section 13.8.

13.6.2 Subject to the rights of Biogen Idec under the Millennium-Biogen
Agreement, Millennium shall control prosecution of all the Biogen Idec
Collaboration Patents and Joint Sunesis-Biogen Collaboration Patents at its own
expense. Sunesis shall control prosecution of all Sunesis Collaboration Patents
at its own expense. Sunesis shall be given the opportunity to review
Millennium’s activities and provide input with respect to Joint Sunesis-Biogen
Collaboration Patents, and Millennium shall in good faith consider including in
such patent applications such claims as Sunesis reasonably requests. Millennium
shall keep Sunesis reasonably informed as to the status of such patent matters,
including by providing Sunesis with (i) copies of any documents relating to
Joint Sunesis-Biogen Collaboration Patents which Millennium receives from any
patent office within twenty (20) days of receipt thereof, including notice of
all interferences, reissues, reexaminations, oppositions or requests for patent
term extensions, and (ii) the opportunity to review and comment on any documents
relating to Joint Sunesis-Biogen Collaboration Patents which will be filed in
any patent office as soon practicable

 

-41-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

but in all cases at least twenty (20) days prior to such filing. All costs
associated with filing, prosecuting, issuing and maintaining the Sunesis Core
Technology shall be borne by Sunesis. In conducting the prosecution activities
described in this Section 13.6.2, each Party shall employ reasonable efforts not
to substantially negatively impact the other Party’s rights under the surviving
provisions of this Agreement.

13.6.3 Millennium’s rights with respect to Co-Funded Products and the Co-Funded
Option shall be as follows:

(a) With respect to any Co-Funded Product for which Sunesis has exercised its
Co-Funding Option, and for which Millennium has not obtained Regulatory Approval
in any territory in the Co-Funded Territory for such Co-Funded Product, in each
case as of the effective date of such termination, such Co-Funded Product shall
become a Reverted Licensed Product in accordance with Section 8.2 and Exhibit
8.2 and Sunesis shall thereafter pay royalties to Millennium on Net Sales of
such Reverted Licensed Product in accordance with Section 6.4.

(b) With respect to any Co-Funded Product for which Sunesis has exercised its
Co-Funding Option, and for which Millennium has obtained Regulatory Approval in
any territory in the Co-Funded Territory for such Co-Funded Product, in each
case as of the effective date of such termination, Sunesis’s rights and
obligations under Section 2.2.3 shall survive, and Millennium shall pay
royalties on any such Co-Funded Products in accordance with Section 6.3.2.
Millennium shall no longer be obligated to provide the detailed plans required
of a Co-Development Plan and Budget to Sunesis, but shall provide Sunesis with
annual budgets of post Phase I Development Costs for any such Co-Funded
Products. Sunesis’s Co-Funding Option with respect to future Licensed Products
shall terminate, as will Article 3, as well as Sunesis’s right to participate in
the JDC under Section 4.3 and any Licensed Product Teams under Section 2.3.

(c) Sunesis’s Co-Funding Option under Section 2.2 with respect to future
Licensed Products shall continue (i.e., with respect to Licensed Products that
are not Co-Funded Products as of the effective date of such termination),
provided that Millennium shall no longer be obligated to provide for each
Licensed Product the detailed plans and clinical data required of an Initial
Development Plan and Phase II Notice pursuant to Section 2.2.1. Millennium
shall, however, provide Sunesis with annual budgets of post Phase I Development
Costs for such Co-Funded Product in accordance with the timetable for a Phase II
Notice set forth in Section 2.2.1, and shall provide reasonable cooperation to
Sunesis in evaluating such Co-Funded Product and the post Phase I Development
Costs related thereto, including consulting with Sunesis in good faith regarding
such annual budgets and the financial, scientific and regulatory assumptions
reflected therein.

13.7. Transition of Information and Materials. With respect to a Party’s
obligation to transition Collaboration Technology, information and material with
respect to a particular Licensed Compound, each Party shall cooperate fully (and
cause its Affiliates to cooperate fully) with the other Party to facilitate a
smooth and prompt transition of Collaboration Technology,

 

-42-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

information and materials that are necessary or useful for the receiving Party
to exercise its licensed rights hereunder with respect to such Licensed
Compound.

13.8. Survival Sections. In addition to the provisions set forth in Sections
13.5.2, 13.5.3 and 13.6 above, as applicable, the following provisions shall
survive the expiration or termination of this Agreement for any reason:
Articles 1 (Definitions), 7 (Payments, Books and Records), 10 (Confidentiality),
11 (Representations and Warranties), 12 (Indemnification), 13 (Term and
Termination), 14 (Dispute Resolution) and 15 (Miscellaneous); and Sections 5.1.1
and 5.1.2.

ARTICLE 14

DISPUTE RESOLUTION

14.1. Escalation to Senior Executives. In the event of a dispute or matter of
significant concern arises between the Parties, then at the request of either
Party, the matter shall be escalated to a senior executive from each Party. Such
senior executive shall be either the CEO of such Party, or another senior
executive of such Party who both reports to the CEO and who has direct
management responsibility for the matter in dispute. Upon such request, such
senior executives shall make themselves reasonably available to meet, and shall
meet either by telephone or if, specifically requested, in person, to attempt to
resolve such matter, and shall thereafter continue to use good faith efforts to
attempt to resolve such matter unless it becomes clear that the matter cannot be
resolved by mutual agreement. Thereafter either Party may pursue such legal
process as is otherwise available under applicable law.

14.2. Injunctive Relief. This Article 14 shall not be construed to prohibit
either Party from seeking preliminary or permanent injunctive relief,
restraining order or degree of specific performance in any court of competent
jurisdiction to the extent not prohibited by this Agreement. For avoidance of
doubt, any such equitable remedies provided under this Article 14 shall be
cumulative and not exclusive and are in addition to any other remedies, which
either Party may have under this Agreement or applicable law.

14.3. Matters to Proceed to Court. Notwithstanding the foregoing, any dispute
relating to the determination of validity of a Party’s patents or other issues
relating solely to a Party’s intellectual property and any dispute asserting
breach of this Agreement or of the representations and warranties made hereunder
shall be submitted exclusively to the federal court in Delaware, and the Parties
hereby consent to the jurisdiction and venue of such court.

ARTICLE 15

MISCELLANEOUS

15.1. Governing Laws. This Agreement and any dispute arising from the
construction, performance or breach hereof shall be governed by and construed,
and enforced in accordance with, the laws of the state of Delaware, without
reference to conflicts of laws principles.

 

-43-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

15.2. Waiver. It is agreed that no waiver by either Party hereto of any breach
or default of any of the covenants or agreements herein set forth shall be
deemed a waiver as to any subsequent or similar breach or default.

15.3. Assignment. This Agreement shall not be assignable by either Party without
the written consent of the other Party hereto, except either Party may assign
this Agreement without such consent to its Affiliates, or to an entity that
acquires all or substantially all of the business or assets of such Party
whether by merger, reorganization, acquisition, sale, or otherwise; provided,
however, that the assignee shall agree in writing to be bound by the terms and
conditions of this Agreement. Notwithstanding any other provision in this
Agreement, [ * ] involving Sunesis shall not be deemed to be a breach of this
Agreement or otherwise require [ * ], provided that such [ * ] shall not [ * ]
to the Sunesis Licensed Patents and Sunesis Core Technology with respect to: the
[ * ]; Biogen Idec Collaboration Patents; Joint Sunesis-Biogen Collaboration
Patents; Development Technology; Other Millennium Technology; and Confidential
Information of Millennium.

15.4. Independent Contractors. The relationship of the Parties hereto is that of
independent contractors. The Parties hereto are not deemed to be agents,
partners or joint venturers of the others for any purpose as a result of this
Agreement or the transactions contemplated thereby.

15.5. Compliance with Laws. In exercising their rights under this license, the
Parties shall fully comply in all material respects with the requirements of any
and all applicable laws, regulations, rules and orders of any governmental body
having jurisdiction over the exercise of rights under this license including
those applicable to the development, manufacture, distribution, import and
export and sale of Products pursuant to this Agreement.

15.6. Patent Marking. Millennium agrees to mark and use reasonable efforts to
make all its Sublicensees mark all Licensed Products sold pursuant to this
Agreement in accordance with the applicable statute or regulations relating to
patent marking in the country or countries of manufacture and sale thereof.
Sunesis agrees to mark and use reasonable efforts to make its Sublicensees mark
all Reverted Licensed Products sold pursuant to this Agreement in accordance
with the applicable statute or regulations relating to patent marking in the
country or countries of manufacture and sale thereof.

15.7. Notices. All notices, requests and other communications hereunder shall be
in writing and shall be personally delivered or by registered or certified mail,
return receipt requested, postage prepaid, in each case to the respective
address specified below, or such other address as may be specified in writing to
the other Parties hereto and shall be deemed to have been given upon receipt:

 

Sunesis:   

Sunesis Pharmaceuticals, Inc.

395 Oyster Point Boulevard, Suite 400

South San Francisco, California 94080

Attn:       Chief Executive Officer

 

-44-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

With a copy to:   

Cooley LLP

3175 Hanover St.

Palo Alto, California 94304-1050

Attn:       Glen Sato

Millennium   

Millennium Pharmaceuticals, Inc.

40 Landsdowne Street

Cambridge, Massachusetts 02139

Attn:       General Counsel

With a copy to:   

Millennium Pharmaceuticals, Inc.

40 Landsdowne Street

Cambridge, Massachusetts 02139

Attn:       Chief Medical Officer

15.8. Severability. In the event that any provision of this Agreement becomes or
is declared by a court of competent jurisdiction to be illegal, unenforceable or
void, this Agreement shall continue in full force and effect to the fullest
extent permitted by law without said provision, and the Parties shall amend the
Agreement to the extent feasible to lawfully include the substance of the
excluded term to as fully as possible realize the intent of the Parties and
their commercial bargain. If a Party seeks to avoid a provision of this
Agreement by asserting that such provision is invalid, illegal or otherwise
unenforceable, the other Party shall have the right to terminate this Agreement
upon sixty (60) days’ prior written notice to the asserting Party, unless such
assertion is eliminated and cured within such sixty (60) day period. If
Millennium has sought to so avoid a provision of this Agreement, such
termination shall be deemed a termination by Millennium under Section 13.4
above, and if Sunesis has sought such an avoidance, such termination shall be
deemed a termination by Millennium for breach by Sunesis under Section 13.2
above.

15.9. Advice of Counsel. Sunesis and Millennium have each consulted counsel of
their choice regarding this Agreement, and each acknowledges and agrees that
this Agreement shall not be deemed to have been drafted by one Party or another
and will be construed accordingly.

15.10. Performance by Affiliates; Warranty. Millennium may exercise any right or
discharge any obligation hereunder through any of its Affiliates. Each Party
hereby warrants and guarantees the performance of any and all rights and
obligations of this Agreement by its Affiliates and Sublicensees.

15.11. Complete Agreement. This Agreement with its Exhibits, together with the
Three Party Agreement, constitutes the entire agreement, both written and oral,
between the Parties with respect to the subject matter hereof, and all prior
agreements respecting the subject matter hereof, either written or oral, express
or implied, shall be abrogated, canceled, and are null and void and of no
effect. No amendment or change hereof or addition hereto shall be effective or
binding on either of the Parties hereto unless reduced to writing and executed
by the respective duly authorized representatives of Sunesis and Millennium.

 

-45-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

15.12. Headings. The captions to the several Sections and Articles hereof are
not a part of this Agreement, but are included merely for convenience of
reference and shall not affect its meaning or interpretation.

15.13. Counterparts. This Agreement may be executed in counterparts, each of
which shall be deemed to be an original and all of which together shall be
deemed to be one and the same agreement.

 

-46-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be duly
executed by their authorized representatives and delivered in duplicate
originals as of the Effective Date.

 

MILLENNIUM PHARMACEUTICALS, INC.      SUNESIS PHARMACEUTICALS, INC. By:  

/s/ Deborah Dunsire, M.D.

     By:  

/s/ Daniel N. Swisher, Jr.

Name:  

Deborah Dunsire, M.D.

     Name:  

Daniel N. Swisher, Jr.

Title:  

Chief Executive Officer

     Title:  

Chief Executive Officer

 

-47-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

EXHIBIT 1.4

Collaboration Patents

RAF Portfolio

 

Country

   Case
Type   Status  

Title

   Filing Date    

Application

Number

   Patent
Number      Grant
Date      Publication
Number   Publication
Date

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]          [ * ]   [ * ]

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]           

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]           

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]           

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]           

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]          [ * ]   [ * ]

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]          [ * ]   [ * ]

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]           

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]           

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]           

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]           

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]           

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]           

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]           

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]           

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]           

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]           

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]           

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]           

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]          [ * ]   [ * ]

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]           

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]           

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]          [ * ]   [ * ]

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]           

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]          [ * ]   [ * ]

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]           

 

-48-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

Country

   Case
Type   Status  

Title

   Filing Date    

Application

Number

   Patent
Number   Grant
Date   Publication
Number   Publication
Date

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]         

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]         

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]        [ * ]   [ * ]

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]        [ * ]   [ * ]

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]         

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]         

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]         

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]         

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]        [ * ]   [ * ]

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]        [ * ]   [ * ]

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]         

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]        [ * ]   [ * ]

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]         

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]         

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]        [ * ]   [ * ]

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]         

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]         

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]         

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]    [ * ]   [ * ]   [ * ]   [ * ]

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]         

[ * ]

   [ * ]   [ * ]   [ * ]      [  * ]    [ * ]        [ * ]   [ * ]

 

-49-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

[ * ] Portfolio

 

Program

   Docket
Number   Country   Case
Type   Status  

Title

   Filing
Date  

Application

Number

   Publication
Number   Publication
Date

[ * ]

   [ * ]   [ * ]   [ * ]   [ * ]   [ * ]    [ * ]   [ * ]    [ * ]   [ * ]

[ * ]

   [ * ]   [ * ]   [ * ]   [ * ]   [ * ]    [ * ]   [ * ]    [ * ]   [ * ]

[ * ]

   [ * ]   [ * ]   [ * ]   [ * ]   [ * ]    [ * ]   [ * ]    [ * ]   [ * ]

[ * ]

   [ * ]   [ * ]   [ * ]   [ * ]   [ * ]    [ * ]   [ * ]     

[ * ]

   [ * ]   [ * ]   [ * ]   [ * ]   [ * ]    [ * ]   [ * ]     

[ * ]

   [ * ]   [ * ]   [ * ]   [ * ]   [ * ]    [ * ]   [ * ]     

[ * ]

   [ * ]   [ * ]   [ * ]   [ * ]   [ * ]    [ * ]   [ * ]    [ * ]   [ * ]

[ * ]

   [ * ]   [ * ]   [ * ]   [ * ]   [ * ]    [ * ]   [ * ]    [ * ]   [ * ]

[ * ]

   [ * ]   [ * ]   [ * ]   [ * ]   [ * ]    [ * ]   [ * ]     

[ * ]

   [ * ]   [ * ]   [ * ]   [ * ]   [ * ]    [ * ]   [ * ]     

[ * ]

   [ * ]   [ * ]   [ * ]   [ * ]   [ * ]    [ * ]   [ * ]     

[ * ]

   [ * ]   [ * ]   [ * ]   [ * ]   [ * ]    [ * ]   [ * ]     

[ * ]

   [ * ]   [ * ]   [ * ]   [ * ]   [ * ]    [ * ]   [ * ]     

 

-50-

--------------------------------------------------------------------------------

EXHIBIT 1.41

Sunesis Core Technology

 

Sunesis

No.

  

Serial No.

  

Title

  

Status

SU-100

  

US

09/105,372

   Methods for Rapidly Identifying Small Organic Molecule Ligands for Binding to
Biological Target Molecules    Issued as U.S. Patent No. 6,335,155

SU-100

D1C1

  

US

10/043,833

   Methods for Rapidly Identifying Small Organic Molecule Ligands for Binding to
Biological Target Molecules    allowed

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

Sunesis

No.

  

Serial No.

  

Title

  

Status

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]

 

-52-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

Sunesis

No.

  

Serial No.

  

Title

  

Status

[ * ]    [ * ]    [ * ]    [ * ] [ * ]    [ * ]    [ * ]    [ * ] [ * ]    [ * ]
   [ * ]    [ * ] [ * ]    [ * ]    [ * ]    [ * ] [ * ]    [ * ]    [ * ]    [
* ] [ * ]    [ * ]    [ * ]    [ * ] [ * ]    [ * ]    [ * ]    [ * ] [ * ]    [
* ]    [ * ]    [ * ] [ * ]       [ * ]    [ * ] [ * ]    [ * ]    [ * ]    [ *
] [ * ]    [ * ]    [ * ]    [ * ] [ * ]    [ * ]    [ * ]    [ * ]

 

-53-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

EXHIBIT 1.44

[ * ] Target Selectivity

[ * ]

 

Name

  

Units/Amount

  

Source

  

Catalog Number

  

Storage

[ * ]

   [ * ]    [ * ]    [ * ]    [ * ]oC

[ * ]

   [ * ]    [ * ]    [ * ]    [ * ]oC

[ * ]

   [ * ]    [ * ]    [ * ]    [ * ]oC

[ * ]

   [ * ]    [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]    [ * ]oC, [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]    [ * ]oC

[ * ]

   [ * ]    [ * ]    [ * ]    [ * ]oC

[ * ]

   [ * ]    [ * ]    [ * ]    [ * ]oC

[ * ]

   [ * ]    [ * ]    [ * ]    [ * ]oC

[ * ]

[ * ] Cellular Assay [ * ]

[ * ]

[ * ] Cellular Assay [ * ]

[ * ]

 

    

1

  

2

  

3

[ * ]

  

4

[ * ]

  

5

[ * ]

  

6

[ * ]

  

7

[ * ]

  

8

[ * ]

  

9

[ * ]

  

10

[ * ]

  

11

  

12

ARTICLE 16A

   [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]
   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]
   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]
   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]
   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]
   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]
   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]
   [ * ]    [ * ]    [ * ]

[ * ]

   [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]
   [ * ]    [ * ]    [ * ]

 

-54-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

[ * ] Enzyme Assay [ * ]

[ * ]

 

    

1

  

2

  

3

  

4

  

5

  

6

  

7

  

8

  

9

  

10

  

11

  

12

ARTICLE 17A    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [
* ]    [ * ]    [ * ]    [ * ]    [ * ] [ * ]    [ * ]    [ * ]    [ * ]    [ *
]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ] [ * ]
   [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]
   [ * ]    [ * ]    [ * ] [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]   
[ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ] [ * ]    [ * ]    [
* ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [
* ]    [ * ] [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ *
]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ] [ * ]    [ * ]    [ * ]    [ * ]
   [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]
[ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]    [ * ]   
[ * ]    [ * ]    [ * ]    [ * ]

[ * ].

 

-55-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

EXHIBIT 8.2

Reverted Licensed Product

Section 1. Reverted Licensed Product.

1.1 Millennium shall cooperate fully with Sunesis and shall provide Sunesis with
all data, documentation, information and materials generated or used by
Millennium in the development, production or other exploitation of such Reverted
Licensed Product, and Sunesis shall have the right to use and disclose such
items.

1.2 To the extent not already terminated, the licenses granted to Millennium
under Section 5.1 shall terminate with respect to such Reverted Licensed
Product.

1.3 All right, title and interest in and to (i) all regulatory filings related
to the Reverted Licensed Product, including all INDs, NDAs and all information
and correspondence related thereto, and (ii) any trademarks specific to the
Reverted Licensed Product shall be transferred and assigned to Sunesis.

1.4 Millennium shall cooperate fully with Sunesis upon Sunesis’s request to
assign to Sunesis, or otherwise secure for Sunesis the benefits of, any
arrangement between Millennium and a Third Party related to the development,
production or exploitation of such Reverted Licensed Product, including clinical
research agreements, manufacturing and supply agreements and distribution
agreements. In the event that such Reverted Licensed Product was manufactured by
Millennium, then Millennium shall continue to provide Sunesis at fully loaded
cost plus a 15% cost of capital charge with quantities of Reverted Licensed
Products reasonably ordered by Sunesis within twelve (12) months after the date
of transition.

1.5 Without limiting the foregoing, Millennium shall use reasonable efforts to
implement the provisions of this Exhibit 8.2 and to ensure orderly transition
and uninterrupted development of the Reverted Licensed Product. Sunesis shall
promptly reimburse Millennium’s reasonable out-of-pocket costs with respect to
activities, services and materials provided by Millennium under Section 1 of
this Exhibit 8.2.

Section 2. Termination of a Reverted Licensed Product and Reversion to
Millennium.

2.1 Sunesis shall cooperate fully with Millennium and shall provide Millennium
with all data, documentation, information and materials generated or used by
Sunesis in the development, production or other exploitation of such Reverted
Licensed Product, and Millennium shall have the right to use and disclose such
items.

2.2 All right, title and interest in and to (i) all regulatory filings related
to such Reverted Licensed Product, including all INDs, NDAs and all information
and correspondence related thereto, and (ii) any trademarks specific to the
Reverted Licensed Product shall be transferred and assigned to Millennium.

 

-56-

--------------------------------------------------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

2.3 Sunesis shall cooperate fully with Millennium upon Millennium’s request to
assign to Millennium, or otherwise secure for Millennium the benefits of, any
arrangement between Sunesis and a Third Party related to the development,
production or exploitation of such Reverted Licensed Product, including clinical
research agreements, manufacturing and supply agreements and distribution
agreements. In the event that such Reverted Licensed Product was manufactured by
Sunesis, then Sunesis shall continue to provide Millennium at fully loaded cost
plus a 15% cost of capital charge with quantities of such Reverted Licensed
Product reasonably ordered by Millennium within twelve (12) months after the
date of transition.

2.4 Without limiting the foregoing, Sunesis shall use reasonable efforts to
implement the provisions of this Exhibit 8.2 and to ensure orderly transition
and uninterrupted development of such Reverted Licensed Product. Millennium
shall promptly reimburse Sunesis’s reasonable out-of-pocket costs with respect
to activities, services and materials provided by Sunesis under Section 2 of
this Exhibit 8.2.

 

-57-